<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Res Ther</journal-id><journal-title-group><journal-title>AIDS Research and Therapy</journal-title></journal-title-group><issn pub-type="epub">1742-6405</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">239</article-id><article-id pub-id-type="doi">10.1186/s12981-019-0239-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>HIV-2 as a model to identify a functional HIV cure</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Esbj&#x000f6;rnsson</surname><given-names>Joakim</given-names></name><address><email>joakim.esbjornsson@med.lu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Jansson</surname><given-names>Marianne</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jespersen</surname><given-names>Sanne</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000e5;nsson</surname><given-names>Fredrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>H&#x000f8;nge</surname><given-names>Bo L.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lindman</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Medina</surname><given-names>Candida</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Zacarias J.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Norrgren</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Medstrand</surname><given-names>Patrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rowland-Jones</surname><given-names>Sarah L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wejse</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Department of Translational Medicine, </institution><institution>Lund University, </institution></institution-wrap>Malm&#x000f6;, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution>Nuffield Department Medicine, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Department of Laboratory Medicine, </institution><institution>Lund University, </institution></institution-wrap>Malm&#x000f6;, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution>Department of Infectious Diseases, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.418811.5</institution-id><institution>Bandim Health Project, Indepth Network, </institution></institution-wrap>Bissau, Guinea-Bissau </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Department of Clinical Sciences Lund, </institution><institution>Lund University, </institution></institution-wrap>Lund, Sweden </aff><aff id="Aff7"><label>7</label>National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau </aff><aff id="Aff8"><label>8</label>National Public Health Laboratory, Bissau, Guinea-Bissau </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution>GloHAU, Center for Global Health, Department of Public Health, </institution><institution>Aarhus University, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Systems Virology, Department of Translational Medicine, </institution><institution>Lund University, </institution></institution-wrap>BMC B13, 221 84 Lund, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>16</volume><elocation-id>24</elocation-id><history><date date-type="received"><day>3</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Two HIV virus types exist: HIV-1 is pandemic and aggressive, whereas HIV-2 is confined mainly to West Africa and less pathogenic. Despite the fact that it has been almost 40&#x000a0;years since the discovery of AIDS, there is still no cure or vaccine against HIV. Consequently, the concepts of functional vaccines and cures that aim to limit HIV disease progression and spread by persistent control of viral replication without life-long treatment have been suggested as more feasible options to control the HIV pandemic. To identify virus-host mechanisms that could be targeted for functional cure development, researchers have focused on a small fraction of HIV-1 infected individuals that control their infection spontaneously, so-called elite controllers. However, these efforts have not been able to unravel the key mechanisms of the infection control. This is partly due to lack in statistical power since only 0.15% of HIV-1 infected individuals are natural elite controllers. The proportion of long-term viral control is larger in HIV-2 infection compared with HIV-1 infection. We therefore present the idea of using HIV-2 as a model for finding a functional cure against HIV. Understanding the key differences between HIV-1 and HIV-2 infections, and the cross-reactive effects in HIV-1/HIV-2 dual-infection could provide novel insights in developing functional HIV cures and vaccines.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HIV-1</kwd><kwd>HIV-2</kwd><kwd>Dual-infection</kwd><kwd>Functional cure</kwd><kwd>Disease progression</kwd><kwd>West Africa</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsr&#x000e5;det</institution></institution-wrap></funding-source><award-id>2016-01417</award-id><principal-award-recipient><name><surname>Esbj&#x000f6;rnsson</surname><given-names>Joakim</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003748</institution-id><institution>Svenska S&#x000e4;llskapet f&#x000f6;r Medicinsk Forskning</institution></institution-wrap></funding-source><award-id>SA-2016</award-id><principal-award-recipient><name><surname>Esbj&#x000f6;rnsson</surname><given-names>Joakim</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>HIV-1 and HIV-2 epidemiology and pathogenesis</title><p id="Par2">HIV-2 was first discovered in 1986 in West Africa [<xref ref-type="bibr" rid="CR1">1</xref>]. Although HIV-2 has been found in other parts of Africa, Europe, India and the United States; West Africa has consistently had the largest HIV-2 prevalence [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. In 1994, the first studies of HIV-2 reported a reduced rate of disease progression compared with HIV-1 among female sex workers in Senegal [<xref ref-type="bibr" rid="CR6">6</xref>]. In 1997, it was reported that HIV-2 infected individuals had twice as high mortality compared with HIV negative individuals in Guinea-Bissau [<xref ref-type="bibr" rid="CR7">7</xref>]. This was confirmed in later studies that showed mortality rates two to fivefold higher in HIV-2 infected individuals compared with HIV-negative individuals in Guinea-Bissau [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Other studies, from The Gambia and France, compared HIV-1 and HIV-2 infection and reported a generally slower CD4+ T-cell decline in HIV-2 infected individuals [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. HIV-2 infected individuals therefore exhibit longer asymptomatic stages than HIV-1 infected individuals [<xref ref-type="bibr" rid="CR12">12</xref>]. However, in individuals reaching AIDS, HIV-1 and HIV-2 share a similar clinical spectrum, with the exception of a lower incidence of Kaposi&#x02019;s sarcoma in HIV-2 infected individuals [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Interestingly, studies have also reported that similar baseline viral load and CD4+ T-cell levels predict similar prognosis for HIV-1 and HIV-2 infected individuals [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. This could indicate that disease prognosis is determined during the early stages of both types of HIV infections.</p><p id="Par3">The viral set-point has been suggested to be 10&#x02013;28 fold lower in HIV-2, with lower levels of viraemia persisting into clinical stages of disease [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. As a consequence, HIV-2 infection is characterized by lower transmission rates at both the horizontal and vertical levels [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Moreover, AIDS seem to occur at a relatively lower viral load level in HIV-2 compared with HIV-1 infection, although the CD4 count is often higher in HIV-2-infected subjects when AIDS-defining illnesses develop [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The lower transmission rates of HIV-2 compared with HIV-1 is further highlighted by the parallel HIV-1 increase and HIV-2 decline seen in West Africa between 1990 and 2010 [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par4">Several reports have indicated that only approximately 15&#x02013;25% of HIV-2 infected individuals will progress to AIDS if following a natural course of disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. However, these assumptions were based on data from HIV-2 infected individuals without information on infection date. On the one hand, lack of infection date will inevitably select for individuals with a slower disease progression rate than the average. On the other hand, such population will also enter the study at a more advanced stage. These biases will create a contradiction that will be difficult to adjust for when estimating true disease progression rates. In 2018, data from individuals with an estimated date of infection showed that the disease trajectory was almost identical between HIV-1 and HIV-2 infections, albeit at approximately half the rate among HIV-2 infected individuals [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Importantly, this showed that AIDS will develop among the majority of HIV-2 infected individuals without antiretroviral treatment (ART). Nevertheless, although no such indication was seen in the study, the existence of a subset of HIV-2-infected subjects who maintain long-term viral control and have a normal life expectancy cannot be entirely excluded since this would require a complete follow-up to the end-stage (AIDS or death) of all study participants [<xref ref-type="bibr" rid="CR27">27</xref>]. However, in such subgroup, the time to AIDS would be longer than the predicted human lifespan, meaning that the age at HIV-2 infection would be a determining factor for the size of the group. In fact, the median age at infection was 38&#x000a0;years in the HIV-2 infected group [<xref ref-type="bibr" rid="CR27">27</xref>]. This, together with the lack of information on infection date, could explain previous results of the high proportion of HIV-2 infected individuals not developing HIV-related disease.</p></sec><sec id="Sec2"><title>HIV-1 and HIV-2 virology and immunology</title><p id="Par5">The HIV-1 and HIV-2 epidemics constitute multiple different introductions of simian immunodeficiency viruses (SIV) into the human population [<xref ref-type="bibr" rid="CR28">28</xref>]. HIV-1 has its origin from SIV of the chimpanzee, whereas HIV-2 originated from the SIV of the sooty mangabey [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Due to the parallel evolution of SIV and HIV in simian and human populations there is a distinct genetic diversity between HIV-1 and HIV-2. To date, a large number of groups, subtypes, subsubtypes and circulating recombinant forms have been described for HIV-1, and at least nine groups of HIV-2 have been described (termed A&#x02013;I) [<xref ref-type="bibr" rid="CR28">28</xref>]. Group A and B are most common in HIV-2 infection, although intergroup recombinants between group A and B has been described [<xref ref-type="bibr" rid="CR30">30</xref>]. However, and despite their different origins, HIV-1 and HIV-2 are related retroviruses and show approximately 55% similarity in Gag and Pol, and 35% similarity in Env on the protein level (the overall similarity level is approximately 55% on the nucleotide level) [<xref ref-type="bibr" rid="CR31">31</xref>]. Although the virus types share transmission routes and target cells, contrasting results in terms of replicative fitness and cytopathicity have been reported [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par6">It is well established that blood plasma viral load is lower in HIV-2 compared with HIV-1 infection [<xref ref-type="bibr" rid="CR34">34</xref>]. It would therefore make sense that viral replication could largely explain the difference in pathogenicity between the two viruses. Studies of natural disease progression caused by HIV-1 have indicated large variations in viral loads between individuals and the difference in plasma viral load may not fully explain the difference in rate of disease progression between the two virus infections. Interestingly, a recent study showed that CD4+ T-cell levels during the asymptomatic stage of infection was stronger associated with HIV-2 disease progression rate than with CD4+ T-cell decline [<xref ref-type="bibr" rid="CR35">35</xref>]. Further studies are therefore needed to determine the causative effects and predictive values of viral load and CD4+ T-cell levels in natural disease progression of both HIV-1 and HIV-2 infection [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par7">It has been suggested that untreated HIV-1 and HIV-2 infected individuals with similar CD4+ T-cell levels have similar levels of <italic>gag</italic> mRNA transcripts, indicating that substantial viral transcription occurs in HIV-2 infected individuals despite the generally lower viral loads [<xref ref-type="bibr" rid="CR38">38</xref>]. Interestingly, the <italic>tat</italic>/<italic>gag</italic> ratio between HIV-1 and HIV-2 infections has been shown to differ [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. Altogether, these studies suggest that <italic>tat</italic> mRNA levels are reduced compared with <italic>gag</italic> mRNA levels in cells from untreated HIV-2 infected individuals, whereas <italic>tat</italic> mRNA levels are more abundant than <italic>gag</italic> mRNA levels in cells from HIV-1 infected individuals. Since <italic>tat</italic> mRNA represents early transcripts, these results could reflect a reduced rate of recent cell infections in HIV-2 infection. It is also possible that post-transcriptional control of viral production could be involved in differences in HIV-1 and HIV-2 pathogenesis [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par8">Lower virus production in HIV-2 compared with HIV-1 infection may also reflect a lower activation state in infected cells, or that HIV-2 is less responsive to activation. The long terminal repeat (LTR) of both HIV-1 and HIV-2 regulates the expression of the virus in response to cellular transcription signals. The HIV-2 LTR differs from HIV-1 in numbers and type of transcription binding elements and enhancers, leading to reduced responsiveness to transcription factors present in activated T-cells [<xref ref-type="bibr" rid="CR43">43</xref>]. It has been shown that the HIV-2 LTR does not respond as well as the HIV-1 LTR to tumour necrosis factor alpha [<xref ref-type="bibr" rid="CR44">44</xref>]. Similar results were obtained in experiments measuring viral replication [<xref ref-type="bibr" rid="CR45">45</xref>]. There could also be differences in activation of HIV-1 and HIV-2 infected cells. In contrast to HIV-1, the HIV-2 envelope glycoprotein was found to stimulate production of higher levels of gamma interferon and interleukin 16 (both inhibit viral replication), and lower levels of interleukin 4 (stimulates viral replication) [<xref ref-type="bibr" rid="CR46">46</xref>]. Further studies may result in novel molecular targets for functional HIV cure strategies.</p><p id="Par9">The latent HIV-1 reservoir has been studied extensively, and the HIV-1 reservoir establishment is associated with the seeding of virus during the acute HIV-1 infection before the adaptive arm of the immune system starts to partially control the virus replication [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. It is also well established that HIV-1 remain quiescent in long-lived CD4+ memory T-cells. Moreover, viral rebound is normally seen only a few weeks after secession of ART even in patients with previous long-term virus suppression. Hence, virus latency in these cells remain one of the main challenges for finding a functional cure against HIV. The size of the virus reservoir has been measured using different protocols, including qPCR of cell-bound virus DNA and mRNA, quantification of ex vivo reactivation of virus mRNA and proteins, as well as in ex vivo virus outgrowth assays. In HIV-1 long-term non-progressors (LTNP) and elite controllers (EC), that have been suggested as models for functional cure, the reservoir of latently infected cells is reduced compared with HIV-1 viraemic and treated individuals [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Interestingly, conflicting results about proviral DNA levels in HIV-2 compared with HIV-1 infection have been reported. Two studies indicated similar proviral levels after adjusting for disease stage [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]; whereas a study by Gueudin et al. [<xref ref-type="bibr" rid="CR40">40</xref>] reported the opposite. Thus, further studies are needed to establish proviral DNA loads at different disease stages of HIV-2 infection, and how they differ from HIV-1 infection. Moreover, even though quantification of virus DNA by qPCR correlate with the size of the latent HIV-1 reservoir, these assays often overestimate the size of the replication competent latent HIV-1 reservoir. Although few studies have characterized the HIV-2 reservoir, it was recently reported that HIV-2 DNA could be quantified in transitional-memory cells from four of 14 ART naive HIV-2-infected individuals, and in central-memory cells from one of 14 ART naive HIV-2-infected individuals [<xref ref-type="bibr" rid="CR41">41</xref>]. Approximately 100 HIV-2 DNA copies/10<sup>6</sup> cells were detected in each of the specific memory cell subsets, respectively. However, HIV-2 in vitro reactivation was only observed in cells from three of the 14 individuals, suggesting presence of defective proviruses. In line with this, the predominance of defective proviral DNA in HIV-2 infected individuals on successful ART has recently been reported from studies of three virally suppressed individuals [<xref ref-type="bibr" rid="CR53">53</xref>]. In this study, most of the HIV-2 genomes had large deletions, whereas hypermutations were noted in a smaller fraction of the sequences. However, complete understanding of the HIV-2 reservoir will require larger studies and the use of different protocols. Moreover, both in vitro and ex vivo studies of latency reversal agents used in HIV-1 clinical settings are needed for HIV-2 (reviewed in [<xref ref-type="bibr" rid="CR54">54</xref>]). Still, from available proviral load data and studies of HIV-1 in LTNP and EC (that in many ways resemble HIV-2) it is plausible that the remission of HIV-2 would be relapse-free or delayed, and less frequent compared with the general HIV-1 case (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Schematic of potential differences between HIV progressor groups in frequency of HIV reactivation from latency. Clearance or control of the latent HIV reservoir remains one of the main obstacles to achieve a functional HIV cure. Although the viral reservoir in HIV-1 infection has been extensively studied, much less is known about the reservoir size or reactivation frequency from this reservoir in HIV-2, and HIV-1 and HIV-2 dual-infection. This figure outlines possible differences in HIV reservoir size and reactivation frequency between the main HIV infection types and progressor groups discussed in this review. The importance of the order of infection in HIV-1 and HIV-2 dual-infection has been highlighted in the figure, and it is likely that the HIV reservoir size and reactivation frequency will differ between depending of the order of HIV infections types</p></caption><graphic xlink:href="12981_2019_239_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par10">Explanations for lower virus loads and reduced pathogenicity in HIV-2 compared with HIV-1 infections have also been attributed to different types of virus-controlling immune responses. Robust, broadly cross-reactive and polyfunctional virus-specific responses of both CD4+ and CD8+ T-cells have been shown to distinguish HIV-2 from HIV-1 infections [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>]. In particular, HIV-2 Gag-specific T-cell responses have been shown to correlate with virus control [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Similarly, CD8+ T-cells co-expressing CD28 have been associated with controlled HIV-2 infection [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Strikingly, when subjects from the &#x0201c;Cai&#x000f3; cohort&#x0201d; with high and undetectable viral loads were compared, the main distinguishing feature was CD8+ T-cell responses to Gag, which were absent in 52% of viraemic participants (the &#x0201c;Cai&#x000f3; cohort&#x0201d; was a large community-based cohort from the small rural village Cai&#x000f3;, Guinea-Bissau) [<xref ref-type="bibr" rid="CR63">63</xref>]. Gag-specific responses in HIV-2-infected subjects often show unusually high functional avidity, with the capacity to respond to picomolar quantities of antigen, and are at an earlier stage of differentiation than HIV-1-specific CD8+ T-cells, presumably retaining their ability to proliferate [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. In line with these observations, HIV-2-specific T-cells from LTNPs in the French cohort showed potent suppression of viral replication, in many cases exceeding the suppressive abilities of HIV-1-specific T-cells from elite controllers [<xref ref-type="bibr" rid="CR64">64</xref>]. Given that high potency HIV-specific cytotoxic T-lymphocytes (CTL) without features of exhaustion and broad cross-reactivity seem to be required for killing of the latent reservoir, there are good arguments to suggest that CTL from HIV-2 infected viral controllers would meet these requirements [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par11">The cellular involvement in modulation of HIV-2 infections within West African populations also comes from HLA associations with viral control (HLA-B*58:01, HLA-DPB1*10:01 and HLA-DRB1*11:01) or disease progression (HLA-B*15:03 and HLA-B*35) [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>]. Furthermore, the function of natural killer (NK) cells appears more well-preserved during asymptomatic HIV-2 compared with HIV-1 infection, whereas the functionality of these cells seem to drop to levels found during HIV-1 infection with declining CD4+ T-cells [<xref ref-type="bibr" rid="CR68">68</xref>]. Similarly to HIV-1 infection, chronic immune activation is linked to immunopathogenesis and progressive disease in HIV-2 infection [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR75">75</xref>]. Elevated frequencies of T-cells expressing markers of activation and exhaustion appear to distinguish HIV-2 infected individuals that progress despite no or low level viraemia, which could be the consequence of long infection duration and/or virus replication not mirrored by plasma RNA levels [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>]. Although these findings could suggest that aviraemic HIV-2 infected individuals should be offered ART, there remains a group of aviraemic individuals with HIV-2 infection without evidence of immune activation who may not necessarily benefit from therapy [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par12">Both potent and broadly neutralizing antibodies have been detected at different disease stages in HIV-2 infection [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR76">76</xref>&#x02013;<xref ref-type="bibr" rid="CR79">79</xref>]. Moreover, although susceptibility of HIV-2 to neutralizing antibodies seem to vary according to the infecting virus strain, it is in general significantly elevated compared to HIV-1 [<xref ref-type="bibr" rid="CR77">77</xref>&#x02013;<xref ref-type="bibr" rid="CR80">80</xref>]. Furthermore, mutants escaping from neutralizing antibodies seem to emerge less frequently in HIV-2 infection and do not reach fixation [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Fc-mediated effector functions, such as the effect of complement on antibody antiviral activity, have also been reported to be potent in HIV-2 infection [<xref ref-type="bibr" rid="CR76">76</xref>]. In addition, antibodies with a broad ability to mediate antibody dependent cellular cytotoxicity (ADCC), and even cross-react with HIV-1, are found in HIV-2 infected individuals [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Thus, despite low-level viraemia, strong antibody responses in HIV-2 infection are sustained during both asymptomatic and progressive HIV-2 infections and do not distinguish between patient groups in different disease stages [<xref ref-type="bibr" rid="CR79">79</xref>]. The impact of antibodies on disease progression during HIV-2 chronic infection is, therefore, not entirely clear.</p><p id="Par13">Finally, animal models for HIV analysis of virus transmission and AIDS development are rare, and chimpanzees are the only non-human primates that are susceptible to HIV-1 infection. However, due to ethics, risk of extinction, and an infection that rarely results in progressive disease, these animals are not used as an infection model for HIV [<xref ref-type="bibr" rid="CR85">85</xref>]. Experimental HIV-2 infection models have instead been established using rhesus and pigtail macaques. Still, these infections mainly result in low or non-pathogenic infections [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. In contrast, serial in vivo passages of HIV-2 in baboons have resulted in the development of an AIDS-like disease model [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. It has also been reported that HIV-2 infection of humanized mice results in persistent viraemia and CD4+ T-cell loss [<xref ref-type="bibr" rid="CR90">90</xref>]. These could therefore represent alternative models for testing efficacy of antiretroviral and latency reversal strategies. As for in vitro models, competition assays between HIV-1 and HIV-2 have demonstrated that the replication fitness of most HIV-2 isolates was lower and outcompeted by HIV-1 isolates [<xref ref-type="bibr" rid="CR32">32</xref>], and others have shown that HIV-2 isolates from aviraemic individuals have reduced in vitro replication capacity compared to HIV-2 isolated during viraemia [<xref ref-type="bibr" rid="CR91">91</xref>].</p></sec><sec id="Sec3"><title>HIV-1 and HIV-2 dual-infection</title><p id="Par14">Dual-infection with HIV-1 and HIV-2 has been reported with a prevalence of up to 3.2% in West Africa [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. However, cross-reactivity in antibody testing and limited molecular testing to distinguish dual-infections have hampered the accuracy of prevalence estimates. Intriguingly, a possible protective effect of HIV-2 on subsequent incident HIV-1 infection was reported in 1995, and several studies reported that HIV-2 could alter HIV-1 infectivity and replication in vitro [<xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR95">95</xref>]. Moreover, HIV-2 infection has been shown to inhibit immunosuppression and simian AIDS after subsequent challenge with pathogenic SIV or SHIV in the Macaque model [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. In 2012, it was shown that HIV-2 could inhibit HIV-1 disease progression also in humans, resulting in almost twice as long time to AIDS and mortality among HIV-1 and HIV-2 dual-infected individuals compared with HIV-1 single-infected individuals [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Importantly, the results showed that the slower disease progression was determined during the establishment of infection, and that the inhibitory effect was strongest among study participants where the HIV-2 infection preceded the HIV-1 infection (indicating the importance of the order of infections, Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Moreover, in-depth analyses of CD4+ T-cell counts and HIV-1 diversity evolution indicated that the main difference between single and dual-infected individuals was determined during early HIV-1 infection. In support, results from the Bissau HIV cohort showed that the median CD4+ T-cell count was higher and the mortality lower in dual-infected individuals compared with HIV-1 single-infected individuals [<xref ref-type="bibr" rid="CR100">100</xref>]. In contrast, a meta-analysis by Prince et al. [<xref ref-type="bibr" rid="CR101">101</xref>] did not show any difference between HIV-1 single, and HIV-1 and HIV-2 dual-infected individuals. However, the data used was extracted from studies that were not designed for comparing survival between single and dual-infected individuals, and lacked information on estimated infection date and infection order among the dual-infected individuals. Most studies suffered from short periods of patient follow-up or observation time, and some were based on hospitalized patients with severe disease already at enrollment. Altogether, if identified, the determinants of the inhibition and slower disease progression in HIV-1 and HIV-2 dual-infection compared with HIV-1 single-infection could represent novel targets suitable for HIV cure strategies or vaccines. Moreover, it is possible that the viral reservoir in HIV-1 and HIV-2 dual-infected individuals is reduced compared to that in the majority of HIV-1 single-infected individuals. Cure strategies in dual-infected individuals may therefore be more successful compared with HIV-1 single-infected individuals (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p></sec><sec id="Sec4"><title>Current functional cure strategies and the possibility of such studies in HIV-2 endemic areas</title><p id="Par15">As the research field of HIV cure has matured over recent years, it has been necessary to define different concepts of the term &#x02018;cure&#x02019; [<xref ref-type="bibr" rid="CR48">48</xref>]. Within HIV-1 cure research, the aspect of &#x02018;functional cure&#x02019; has emerged, or lately &#x02018;relapse-free remission&#x02019; to define sustained suppression of virus without the need for ART. This means that a &#x02018;functional cure&#x02019; does not have to result in complete absence of HIV in the body. Several different cure strategies have been suggested, e.g. stimulation of the latently infected cells to reduce the reservoir size; gene therapy to reduce the number of target cells; and immunotherapy to ameliorate the HIV-specific immune response [<xref ref-type="bibr" rid="CR102">102</xref>&#x02013;<xref ref-type="bibr" rid="CR105">105</xref>]. An example of naturally occurring &#x02018;functional cure&#x02019; are so-called elite controllers, which has been described in a small minority of HIV-1 patients [<xref ref-type="bibr" rid="CR106">106</xref>&#x02013;<xref ref-type="bibr" rid="CR108">108</xref>]. Interestingly, this phenomenon seems to be much more frequent among HIV-2 infected individuals, and it is largely unknown why this is the case [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, there are important lessons to be learned from HIV-2 pathogenesis, and HIV-2 may represent a model to study relapse-free remission and open up new avenues towards how to induce relapse-free remission in HIV-1 infection (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par16">Antiretroviral treatment effectively suppresses, but does not cure HIV infection. Multiple therapeutic strategies have been pursued in HIV cure research, but there has been a particular focus on using latency-reversing-agents (LRAs) such as histone deacetylase inhibitors (HDACi), disulfiram, Protein C kinase agonists and Toll-like Receptor agonists, to activate HIV-expression in latently infected cells, and thereby exposing their infected status to the immune system and potentially facilitating immune or virus-mediated cell lysis [<xref ref-type="bibr" rid="CR109">109</xref>]. This is usually termed &#x0201c;shock-and-kill&#x0201d; [<xref ref-type="bibr" rid="CR103">103</xref>]. Yet, although clinical trials of many of these compounds have demonstrated that HIV latency can be disrupted in individuals on suppressive ART, this does not lead to a reduction in the frequency of latently infected cells or delayed viral rebound during analytical interruption of ART [<xref ref-type="bibr" rid="CR110">110</xref>]. More recently, attempts to reverse latency with compounds that both activate virus and modulate immunity to enhance clearance of infected cells (so-called immunomodulatory LRAs), have been made [<xref ref-type="bibr" rid="CR89">89</xref>]. The inability of latency-reversal interventions to impact the latent HIV reservoir in clinical trials has increased the scientific focus on immune-enhancement strategies towards a concept of relapse-free remission after cessation of therapy. This is also supported by the demonstration that even in individuals with no or extremely low levels of HIV in cells or plasma, there is rebound viraemia when ART is stopped [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. This emphasizes that an effective strategy to achieve long-term ART-free remission should include both a component that reduces the amount of HIV that persists on ART, and a component that improves anti-HIV immune surveillance of residual viruses. This could involve immune-based therapies with immune checkpoint inhibitors, TLR agonists, or HIV-specific broadly neutralising antibodies, which are currently under intense investigation for application in HIV prevention, treatment and cure [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR113">113</xref>&#x02013;<xref ref-type="bibr" rid="CR115">115</xref>]. Additionally, starting ART shortly after infection has been a focus area, as this is associated with both a lower frequency of latently infected CD4+ T-cells in blood and tissue, and a better preserved T-cell function [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. Furthermore, early ART increases the likelihood of post-treatment control, i.e. the ability to achieve durable remission after interruption of ART, which was started in primary infection&#x02014;a phenomenon initially described in the French VISCONTI cohort [<xref ref-type="bibr" rid="CR118">118</xref>].</p><p id="Par17">Despite recent disappointments on the possibility of LRAs leading to longstanding remission in HIV-1, there could be a case for trying LRAs and &#x0201c;shock-and-kill&#x0201d; therapies in HIV-2, since it may be a less fit and more sensitive virus. HIV-2 cytotoxic CD8+ T-cell responses and possibly antibody responses, either broadly neutralizing or mediating ADCC, may partly explain the delayed progression of HIV-1 in patients firstly infected with HIV-2 and later superinfected with HIV-1 [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR77">77</xref>&#x02013;<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR119">119</xref>&#x02013;<xref ref-type="bibr" rid="CR123">123</xref>]. Hence, if HIV-2 immune responses play a role in controlling the rate of HIV-1 disease progression in individuals with dual-infection, it is plausible that boosting immunity may be able to induce relapse-free remission in HIV-2. There is a need to elicit studies on remission-strategies among HIV-2 infected individuals as these studies hold important promises for achieving an increased understanding of how to achieve remission in HIV-1.</p><p id="Par18">An important question is if there is sufficient capacity to undertake a functional cure study based on HIV-2 in the field sites where there is a sufficient number of relevant HIV-2 cases. There are undoubtedly numerous factors to take into consideration before embarking on such highly complex clinical trials, and a number of relevant concerns need to be taken into account (summarised in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Yet, these are all manageable challenges that have been overcome in previous studies (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). For example, both the Bissau HIV cohort and the Guinea-Bissau police cohort have built a high standard trial capacity during the last decades. Moreover, a therapeutic HIV-1 vaccine trial has already been completed in the Bissau HIV cohort [<xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. Despite limited settings, large HIV treatment trials such as the PIONA trial have been possible through an experienced clinical trial unit that is still in place in Bissau, Guinea-Bissau [<xref ref-type="bibr" rid="CR126">126</xref>]. This trial unit has the capacity to handle 10&#x02013;20 annual project visits that such trials may entail, as well as provide complex treatments requiring long infusions. The set-up for advanced analyses of immune-mediated processes is in place, both locally and among external partners [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>]. Finally, more collaborations are needed in order to fully take on the many possibilities within this emerging field of HIV-2 cure research, and the Bissau cohorts are open to any collaborative efforts in this area and possible HIV cure applications.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Strengths and weaknesses of the Bissau HIV and the Guinea-Bissau police cohorts and associated research teams</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Strengths</th><th align="left">Weaknesses</th></tr></thead><tbody><tr><td align="left">World&#x02019;s largest HIV-2 cohort&#x02009;+&#x02009;professional cohort with long and frequent follow-up [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]</td><td align="left">High mortality and loss-to-follow-up</td></tr><tr><td align="left">HIV-2 epidemiology well-characterized over three decades [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left"/></tr><tr><td align="left">Nationwide cohort [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]</td><td align="left">High patient-turnaround and insufficient staff-resources</td></tr><tr><td align="left">Strong collaboration with the National Health Laboratory in Guinea-Bissau</td><td align="left">Limited lab capacity locally</td></tr><tr><td align="left">Large biorepository with preserved plasma and DNA</td><td align="left">Limited sample volume in historical samples</td></tr><tr><td align="left">Cohort clinical real-time database including demographics and follow-up data [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR133">133</xref>&#x02013;<xref ref-type="bibr" rid="CR135">135</xref>]</td><td align="left">Limited data-entry capacity and political instability [<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td align="left">Close linkage with HIV-cure research environment and in-depth molecular analysis, including access to humanized mice models, ex vivo infection models, full-length genome sequencing and construction of infectious chimeric viruses [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR141">141</xref>]</td><td align="left">Weak local research environment with few nationals at Ph.D level</td></tr><tr><td align="left">Well-functioning national ethical committee with enhanced understanding for the complex ethical balancing needed for cure trials</td><td align="left">Low health literacy among HIV patients, and extended information and consent procedure needed</td></tr><tr><td align="left">National ethics committee placed within Ministry of Health, and a permission also serves as official government authorization for interventions to be tested</td><td align="left">Limited experience among official health authorities for approval of non-approved drugs</td></tr><tr><td align="left">Burden of co-infections and other comorbidities [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR142">142</xref>&#x02013;<xref ref-type="bibr" rid="CR151">151</xref>]</td><td align="left">Limited local diagnostic capacity for a number of co-infections</td></tr><tr><td align="left">Resistance testing of HIV-1 [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]</td><td align="left">Limited local capacity for genotypic resistance, and non-existing for HIV-2</td></tr><tr><td align="left">Well-described algorithms for the diagnostic challenges of differentiating HIV-2 and dual-infections [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR154">154</xref>&#x02013;<xref ref-type="bibr" rid="CR160">160</xref>]</td><td align="left">Not the entire cohort tested with updated HIV-2 and HIV-1/HIV-2 dual diagnostics, needs retesting prior to trials</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Challenges with performing an HIV cure trial in Guinea-Bissau and strategies to overcome these</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Challenges for HIV cure trials</th><th align="left">Strategies to manage challenges</th></tr></thead><tbody><tr><td align="left">Reluctance to accept high volume blood samples if not sick</td><td align="left">Consent for 10 ml EDTA can usually be obtained</td></tr><tr><td align="left">Keeping the cold chain</td><td align="left">Samples can be transported in cooler to National Health Laboratory and placed in &#x02212;&#x02009;80&#x000a0;&#x000b0;C freezer or on dried ice</td></tr><tr><td align="left">Cell recovery</td><td align="left">Standards for transport of viable PBMCs in place to be analysed elsewhere [<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left">Ethical concerns for vulnerable HIV population with limited health literacy [<xref ref-type="bibr" rid="CR161">161</xref>]</td><td align="left">Audio-visual teaching materials can be produced to inform patients relevantly for informed consent</td></tr><tr><td align="left">Taboo/stigma of HIV</td><td align="left">Staff trained in enrolling and following patients on trials without breaching confidentiality and keeping HIV a secret to other family members in the house</td></tr><tr><td align="left">Loss-to-follow-up [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]</td><td align="left">Strategies to reduce loss-to-follow-up, including staff trained in mobile phone contact and home visits in place [<xref ref-type="bibr" rid="CR163">163</xref>]</td></tr><tr><td align="left">Considerable adherence challenges, difficult to achieve long-term viral rebound-free treatment [<xref ref-type="bibr" rid="CR164">164</xref>]</td><td align="left">Within the framework of a clinical trial, adherence and follow-up can be improved [<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par19">HIV-2 is a less pathogenic virus than HIV-1, disease progression is slower and the proportions of controllers and slow progressors are higher. Both cellular and humoral immune responses, particularly HIV-2-specific CD8+ T-cell responses, are likely to play a role in controlling the rate of disease progression in individuals with dual-infection. A main immunological correlate for the substantial proportion of the aviraemic slow progressors seen in HIV-2 infection is the presence of highly avid, early-differentiated polyfunctional Gag-specific CTL (potentially more effective at targeting reactivated latent virus than HIV-1-specific T-cells). Therefore, there are important lessons to be learned from HIV-2 pathogenesis, and HIV-2 may represent a model to study relapse-free remission in HIV-1 infection (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Understanding the key differences between HIV-1 and HIV-2 infections, and the cross-reactive effects in HIV-1/HIV-2 dual-infection could provide novel insights in developing functional HIV cures and vaccines. There is a clear need to conduct studies on remission-strategies among HIV-2 infected individuals as these studies would provide valuable insights for achieving HIV cure.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank Dr. Thomas Asgaard for valuable input on the manuscript before submission.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors contributed in writing the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>J.E. was supported by the Swedish Research Council (No. 2016-01417), the Swedish Society of Medical Research (SA-2016), and the Medical Faculty at Lund University.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par20">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par21">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par22">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavel</surname><given-names>F</given-names></name><name><surname>Guetard</surname><given-names>D</given-names></name><name><surname>Brun-Vezinet</surname><given-names>F</given-names></name><name><surname>Chamaret</surname><given-names>S</given-names></name><name><surname>Rey</surname><given-names>M</given-names></name><name><surname>Santos-Ferreira</surname><given-names>M</given-names></name><etal/></person-group><article-title>Isolation of a new human retrovirus from West African patients with AIDS</article-title><source>Science</source><year>1986</year><volume>233</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1126/science.2425430</pub-id><?supplied-pmid 2425430?><pub-id pub-id-type="pmid">2425430</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Oliveira</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Dias</surname><given-names>F</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Holmgren</surname><given-names>B</given-names></name><etal/></person-group><article-title>Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?</article-title><source>Aids</source><year>2008</year><volume>22</volume><issue>10</issue><fpage>1195</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328300a33d</pub-id><?supplied-pmid 18525265?><pub-id pub-id-type="pmid">18525265</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Silva</surname><given-names>TI</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><name><surname>Rowland-Jones</surname><given-names>SL</given-names></name></person-group><article-title>HIV-2: the forgotten AIDS virus</article-title><source>Trends Microbiol</source><year>2008</year><volume>16</volume><issue>12</issue><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2008.09.003</pub-id><?supplied-pmid 18964021?><pub-id pub-id-type="pmid">18964021</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Dias</surname><given-names>F</given-names></name><name><surname>Nilsson</surname><given-names>LA</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa</article-title><source>Aids</source><year>2009</year><volume>23</volume><issue>12</issue><fpage>1575</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32832cedfb</pub-id><?supplied-pmid 19521234?><pub-id pub-id-type="pmid">19521234</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Loeff</surname><given-names>MF</given-names></name><name><surname>Awasana</surname><given-names>AA</given-names></name><name><surname>Sarge-Njie</surname><given-names>R</given-names></name><name><surname>van der Sande</surname><given-names>M</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><name><surname>Sabally</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2</article-title><source>Int J Epidemiol</source><year>2006</year><volume>35</volume><issue>5</issue><fpage>1322</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1093/ije/dyl037</pub-id><?supplied-pmid 16543363?><pub-id pub-id-type="pmid">16543363</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>M</given-names></name><name><surname>Phyllis</surname><given-names>K</given-names></name><name><surname>Ibou</surname><given-names>T</given-names></name><name><surname>Karin</surname><given-names>T</given-names></name><name><surname>Geoffrey</surname><given-names>E</given-names></name><name><surname>Tidiane</surname><given-names>S</given-names></name><etal/></person-group><article-title>Reduced rate of disease development after HIV-2 infection as compared to HIV-1</article-title><source>Science</source><year>1994</year><volume>265</volume><issue>5178</issue><fpage>1587</fpage><pub-id pub-id-type="doi">10.1126/science.7915856</pub-id><pub-id pub-id-type="pmid">7915856</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>A-G</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name></person-group><article-title>9-year HIV-2-associated mortality in an urban community in Bissau, west Africa</article-title><source>Lancet</source><year>1997</year><volume>349</volume><issue>9056</issue><fpage>911</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)04402-9</pub-id><?supplied-pmid 9093252?><pub-id pub-id-type="pmid">9093252</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmgren</surname><given-names>B</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Vastrup</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>O</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Ravn</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau</article-title><source>Retrovirology</source><year>2007</year><volume>4</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-4-85</pub-id><?supplied-pmid 18042276?><pub-id pub-id-type="pmid">18042276</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>Da Silva</surname><given-names>ZJ</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Biague</surname><given-names>JA</given-names></name><name><surname>Dias</surname><given-names>F</given-names></name><name><surname>Biberfeld</surname><given-names>G</given-names></name><etal/></person-group><article-title>Clinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau</article-title><source>Scand J Infect Dis</source><year>1998</year><volume>30</volume><issue>4</issue><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1080/00365549850160585</pub-id><?supplied-pmid 9817509?><pub-id pub-id-type="pmid">9817509</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffar</surname><given-names>S</given-names></name><name><surname>Wilkins</surname><given-names>A</given-names></name><name><surname>Ngom</surname><given-names>PT</given-names></name><name><surname>Sabally</surname><given-names>S</given-names></name><name><surname>Corrah</surname><given-names>T</given-names></name><name><surname>Bangali</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection</article-title><source>J Acquir Immune Defic Syndr Hum Retrovirol</source><year>1997</year><volume>16</volume><issue>5</issue><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1097/00042560-199712150-00003</pub-id><?supplied-pmid 9420309?><pub-id pub-id-type="pmid">9420309</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drylewicz</surname><given-names>J</given-names></name><name><surname>Matheron</surname><given-names>S</given-names></name><name><surname>Lazaro</surname><given-names>E</given-names></name><name><surname>Damond</surname><given-names>F</given-names></name><name><surname>Bonnet</surname><given-names>F</given-names></name><name><surname>Simon</surname><given-names>F</given-names></name><etal/></person-group><article-title>Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France</article-title><source>Aids</source><year>2008</year><volume>22</volume><issue>4</issue><fpage>457</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3282f4ddfc</pub-id><?supplied-pmid 18301058?><pub-id pub-id-type="pmid">18301058</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Kvist</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Fenyo</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study</article-title><source>Lancet HIV</source><year>2018</year><volume>6</volume><fpage>e25</fpage><lpage>e31</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(18)30254-6</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariyoshi</surname><given-names>K</given-names></name><name><surname>Schim van der Loeff</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>P</given-names></name><name><surname>Whitby</surname><given-names>D</given-names></name><name><surname>Corrah</surname><given-names>T</given-names></name><name><surname>Jaffar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Kaposi&#x02019;s sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8</article-title><source>J Hum Virol</source><year>1998</year><volume>1</volume><issue>3</issue><fpage>193</fpage><lpage>199</lpage><?supplied-pmid 10195242?><pub-id pub-id-type="pmid">10195242</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Steele</surname><given-names>E</given-names></name><name><surname>Awasana</surname><given-names>AA</given-names></name><name><surname>Corrah</surname><given-names>T</given-names></name><name><surname>Sabally</surname><given-names>S</given-names></name><name><surname>van der Sande</surname><given-names>M</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><etal/></person-group><article-title>Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic</article-title><source>Aids</source><year>2007</year><volume>21</volume><issue>3</issue><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328011d7ab</pub-id><?supplied-pmid 17255738?><pub-id pub-id-type="pmid">17255738</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>GS</given-names></name><name><surname>Sow</surname><given-names>PS</given-names></name><name><surname>Hawes</surname><given-names>SE</given-names></name><name><surname>Ndoye</surname><given-names>I</given-names></name><name><surname>Redman</surname><given-names>M</given-names></name><name><surname>Coll-Seck</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa</article-title><source>J Infect Dis</source><year>2002</year><volume>185</volume><issue>7</issue><fpage>905</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1086/339295</pub-id><?supplied-pmid 11920314?><pub-id pub-id-type="pmid">11920314</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansmann</surname><given-names>A</given-names></name><name><surname>Loeff</surname><given-names>MF</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Awasana</surname><given-names>AA</given-names></name><name><surname>Sarge-Njie</surname><given-names>R</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia</article-title><source>J Acquir Immune Defic Syndr</source><year>2005</year><volume>38</volume><issue>3</issue><fpage>335</fpage><lpage>341</lpage><?supplied-pmid 15735454?><pub-id pub-id-type="pmid">15735454</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><name><surname>Bamba</surname><given-names>S</given-names></name><name><surname>Kwok</surname><given-names>S</given-names></name><etal/></person-group><article-title>Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><issue>21</issue><fpage>3286</fpage><lpage>3293</lpage><pub-id pub-id-type="doi">10.1001/archinte.160.21.3286</pub-id><?supplied-pmid 11088091?><pub-id pub-id-type="pmid">11088091</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Petersen</surname><given-names>MS</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te David</surname><given-names>DS</given-names></name><name><surname>Kjerulff</surname><given-names>B</given-names></name><etal/></person-group><article-title>T and B-cell perturbations identify distinct differences in HIV-2 compared with HIV-1 induced immunodeficiency</article-title><source>Aids</source><year>2019</year><volume>33</volume><fpage>1131</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002184</pub-id><?supplied-pmid 30845070?><pub-id pub-id-type="pmid">30845070</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanki</surname><given-names>PJ</given-names></name><name><surname>Travers</surname><given-names>KU</given-names></name></person-group><article-title>Slower heterosexual spread of HIV-2 than HIV-1</article-title><source>Lancet</source><year>1994</year><volume>343</volume><issue>8903</issue><fpage>93</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)90065-5</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donovan</surname><given-names>D</given-names></name><name><surname>Ariyoshi</surname><given-names>K</given-names></name><name><surname>Milligan</surname><given-names>P</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Yamuah</surname><given-names>L</given-names></name><name><surname>Sarge-Njie</surname><given-names>R</given-names></name><etal/></person-group><article-title>Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia</article-title><source>AIDS</source><year>2000</year><volume>14</volume><issue>4</issue><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1097/00002030-200003100-00019</pub-id><?supplied-pmid 10770548?><pub-id pub-id-type="pmid">10770548</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyamweya</surname><given-names>S</given-names></name><name><surname>Hegedus</surname><given-names>A</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><name><surname>Rowland-Jones</surname><given-names>S</given-names></name><name><surname>Flanagan</surname><given-names>KL</given-names></name><name><surname>Macallan</surname><given-names>DC</given-names></name></person-group><article-title>Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis</article-title><source>Rev Med Virol</source><year>2013</year><volume>23</volume><issue>4</issue><fpage>221</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1002/rmv.1739</pub-id><?supplied-pmid 23444290?><pub-id pub-id-type="pmid">23444290</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>JS</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><etal/></person-group><article-title>HIV-2 continues to decrease, whereas HIV-1 is stabilizing in Guinea-Bissau</article-title><source>Aids</source><year>2018</year><volume>32</volume><issue>9</issue><fpage>1193</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001827</pub-id><?supplied-pmid 29683842?><pub-id pub-id-type="pmid">29683842</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>S</given-names></name><name><surname>Vranckx</surname><given-names>L</given-names></name><name><surname>Gijsbers</surname><given-names>R</given-names></name><name><surname>Christ</surname><given-names>F</given-names></name><name><surname>Debyser</surname><given-names>Z</given-names></name></person-group><article-title>Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection</article-title><source>J Virus Erad</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage><?supplied-pmid 28275453?><pub-id pub-id-type="pmid">28275453</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchounga</surname><given-names>B</given-names></name><name><surname>Ekouevi</surname><given-names>DK</given-names></name><name><surname>Balestre</surname><given-names>E</given-names></name><name><surname>Dabis</surname><given-names>F</given-names></name></person-group><article-title>Mortality and survival patterns of people living with HIV-2</article-title><source>Curr Opin HIV AIDS</source><year>2016</year><volume>11</volume><issue>5</issue><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000299</pub-id><?supplied-pmid 27254747?><pub-id pub-id-type="pmid">27254747</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Lindman</surname><given-names>J</given-names></name><name><surname>Rowland-Jones</surname><given-names>SL</given-names></name><name><surname>Jansson</surname><given-names>M</given-names></name><name><surname>Medstrand</surname><given-names>P</given-names></name><etal/></person-group><article-title>New insights are game-changers in HIV-2 disease management&#x02014;Authors&#x02019; reply</article-title><source>Lancet HIV</source><year>2019</year><volume>6</volume><issue>4</issue><fpage>e214</fpage><lpage>e215</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30089-X</pub-id><?supplied-pmid 30942185?><pub-id pub-id-type="pmid">30942185</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name></person-group><article-title>Is it time to revise the notion that HIV-2 is benign?</article-title><source>Lancet HIV</source><year>2018</year><volume>6</volume><fpage>e3</fpage><lpage>e4</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(18)30265-0</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Loeff</surname><given-names>MF</given-names></name><name><surname>Larke</surname><given-names>N</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Berry</surname><given-names>N</given-names></name><name><surname>Ariyoshi</surname><given-names>K</given-names></name><name><surname>Alabi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village</article-title><source>Retrovirology</source><year>2010</year><volume>7</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-7-46</pub-id><?supplied-pmid 20482865?><pub-id pub-id-type="pmid">20482865</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>D</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><article-title>Key viral adaptations preceding the AIDS pandemic</article-title><source>Cell Host Microbe</source><year>2019</year><volume>25</volume><issue>1</issue><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.12.002</pub-id><?supplied-pmid 30629915?><pub-id pub-id-type="pmid">30629915</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Bailes</surname><given-names>E</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Rodenburg</surname><given-names>CM</given-names></name><name><surname>Michael</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes</article-title><source>Nature</source><year>1999</year><volume>397</volume><issue>6718</issue><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/17130</pub-id><?supplied-pmid 9989410?><pub-id pub-id-type="pmid">9989410</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>ML</given-names></name><name><surname>Range</surname><given-names>F</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bailes</surname><given-names>E</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><etal/></person-group><article-title>Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d&#x02019;Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>19</issue><fpage>12515</fpage><lpage>12527</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.19.12515-12527.2005</pub-id><?supplied-pmid 16160179?><pub-id pub-id-type="pmid">16160179</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motomura</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>WS</given-names></name></person-group><article-title>Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>4</issue><fpage>1923</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1128/JVI.01937-07</pub-id><?supplied-pmid 18057256?><pub-id pub-id-type="pmid">18057256</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arien</surname><given-names>KK</given-names></name><name><surname>Abraha</surname><given-names>A</given-names></name><name><surname>Quinones-Mateu</surname><given-names>ME</given-names></name><name><surname>Kestens</surname><given-names>L</given-names></name><name><surname>Vanham</surname><given-names>G</given-names></name><name><surname>Arts</surname><given-names>EJ</given-names></name></person-group><article-title>The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>14</issue><fpage>8979</fpage><lpage>8990</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.14.8979-8990.2005</pub-id><?supplied-pmid 15994792?><pub-id pub-id-type="pmid">15994792</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland-Jones</surname><given-names>S</given-names></name></person-group><article-title>Protective immunity against HIV infection: lessons from HIV-2 infection</article-title><source>Future Microbiol</source><year>2006</year><volume>1</volume><issue>4</issue><fpage>427</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.2217/17460913.1.4.427</pub-id><?supplied-pmid 17661633?><pub-id pub-id-type="pmid">17661633</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popper</surname><given-names>SJ</given-names></name><name><surname>Sarr</surname><given-names>AD</given-names></name><name><surname>Travers</surname><given-names>KU</given-names></name><name><surname>Gueye-Ndiaye</surname><given-names>A</given-names></name><name><surname>Mboup</surname><given-names>S</given-names></name><name><surname>Essex</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2</article-title><source>J Infect Dis</source><year>1999</year><volume>180</volume><issue>4</issue><fpage>1116</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1086/315010</pub-id><?supplied-pmid 10479138?><pub-id pub-id-type="pmid">10479138</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palm</surname><given-names>AA</given-names></name><name><surname>Lemey</surname><given-names>P</given-names></name><name><surname>Jansson</surname><given-names>M</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Kvist</surname><given-names>A</given-names></name><name><surname>Szojka</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Low postseroconversion CD4(+) T-cell level is associated with faster disease progression and higher viral evolutionary rate in HIV-2 infection</article-title><source>MBio</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>e01245-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01245-18</pub-id><?supplied-pmid 30622192?><pub-id pub-id-type="pmid">30622192</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>RM</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Kingsley</surname><given-names>LA</given-names></name></person-group><article-title>Prognosis in HIV-1 infection predicted by the quantity of virus in plasma</article-title><source>Science</source><year>1996</year><volume>272</volume><issue>5265</issue><fpage>1167</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1126/science.272.5265.1167</pub-id><?supplied-pmid 8638160?><pub-id pub-id-type="pmid">8638160</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>B</given-names></name><name><surname>Sethi</surname><given-names>AK</given-names></name><name><surname>Cheruvu</surname><given-names>VK</given-names></name><name><surname>Mackay</surname><given-names>W</given-names></name><name><surname>Bosch</surname><given-names>RJ</given-names></name><name><surname>Kitahata</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection</article-title><source>JAMA</source><year>2006</year><volume>296</volume><issue>12</issue><fpage>1498</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1001/jama.296.12.1498</pub-id><?supplied-pmid 17003398?><pub-id pub-id-type="pmid">17003398</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>RS</given-names></name><name><surname>Tendeiro</surname><given-names>R</given-names></name><name><surname>Foxall</surname><given-names>RB</given-names></name><name><surname>Baptista</surname><given-names>AP</given-names></name><name><surname>Cavaleiro</surname><given-names>R</given-names></name><name><surname>Gomes</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>5</issue><fpage>2429</fpage><lpage>2438</lpage><pub-id pub-id-type="doi">10.1128/JVI.01921-10</pub-id><?supplied-pmid 21159859?><pub-id pub-id-type="pmid">21159859</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonza</surname><given-names>S</given-names></name><name><surname>Mutimer</surname><given-names>HP</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>K</given-names></name><name><surname>Ellery</surname><given-names>P</given-names></name><name><surname>Howard</surname><given-names>JL</given-names></name><name><surname>Axelrod</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages</article-title><source>J Virol</source><year>2002</year><volume>76</volume><issue>24</issue><fpage>12611</fpage><lpage>12621</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.24.12611-12621.2002</pub-id><?supplied-pmid 12438587?><pub-id pub-id-type="pmid">12438587</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gueudin</surname><given-names>M</given-names></name><name><surname>Damond</surname><given-names>F</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Taieb</surname><given-names>A</given-names></name><name><surname>Lemee</surname><given-names>V</given-names></name><name><surname>Plantier</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Differences in proviral DNA load between HIV-1- and HIV-2-infected patients</article-title><source>Aids</source><year>2008</year><volume>22</volume><issue>2</issue><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3282f42429</pub-id><?supplied-pmid 18097223?><pub-id pub-id-type="pmid">18097223</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samri</surname><given-names>A</given-names></name><name><surname>Charpentier</surname><given-names>C</given-names></name><name><surname>Diallo</surname><given-names>MS</given-names></name><name><surname>Bertine</surname><given-names>M</given-names></name><name><surname>Even</surname><given-names>S</given-names></name><name><surname>Morin</surname><given-names>V</given-names></name><etal/></person-group><article-title>Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR41 co-receptor expression in attenuated HIV-2 infection</article-title><source>PLoS Pathog</source><year>2019</year><volume>15</volume><issue>5</issue><fpage>e1007758</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1007758</pub-id><?supplied-pmid 31095640?><pub-id pub-id-type="pmid">31095640</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes-Cabaco</surname><given-names>H</given-names></name><name><surname>Matoso</surname><given-names>P</given-names></name><name><surname>Foxall</surname><given-names>RB</given-names></name><name><surname>Tendeiro</surname><given-names>R</given-names></name><name><surname>Pires</surname><given-names>AR</given-names></name><name><surname>Carvalho</surname><given-names>T</given-names></name><etal/></person-group><article-title>Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes</article-title><source>J Virol</source><year>2015</year><volume>89</volume><issue>4</issue><fpage>2201</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1128/JVI.03047-14</pub-id><?supplied-pmid 25473058?><pub-id pub-id-type="pmid">25473058</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>NM</given-names></name><name><surname>Hannibal</surname><given-names>MC</given-names></name><name><surname>Markovitz</surname><given-names>DM</given-names></name></person-group><article-title>The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells</article-title><source>J Virol</source><year>1995</year><volume>69</volume><issue>8</issue><fpage>4854</fpage><lpage>4862</lpage><?supplied-pmid 7609053?><pub-id pub-id-type="pmid">7609053</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannibal</surname><given-names>MC</given-names></name><name><surname>Markovitz</surname><given-names>DM</given-names></name><name><surname>Clark</surname><given-names>N</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><article-title>Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals</article-title><source>J Virol</source><year>1993</year><volume>67</volume><issue>8</issue><fpage>5035</fpage><lpage>5040</lpage><?supplied-pmid 8331739?><pub-id pub-id-type="pmid">8331739</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong-Starksen</surname><given-names>SE</given-names></name><name><surname>Welsh</surname><given-names>TM</given-names></name><name><surname>Peterlin</surname><given-names>BM</given-names></name></person-group><article-title>Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals</article-title><source>J Immunol</source><year>1990</year><volume>145</volume><issue>12</issue><fpage>4348</fpage><lpage>4354</lpage><?supplied-pmid 2258623?><pub-id pub-id-type="pmid">2258623</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekigawa</surname><given-names>I</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Neoh</surname><given-names>LP</given-names></name><name><surname>Takeda-Hirokawa</surname><given-names>N</given-names></name><name><surname>Akimoto</surname><given-names>H</given-names></name><name><surname>Hishikawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Differences of HIV envelope protein between HIV-1 and HIV-2: possible relation to the lower virulence of HIV-2</article-title><source>Viral Immunol</source><year>1998</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1089/vim.1998.11.1</pub-id><?supplied-pmid 9586692?><pub-id pub-id-type="pmid">9586692</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>Targeting the latent reservoir for HIV-1</article-title><source>Immunity</source><year>2018</year><volume>48</volume><issue>5</issue><fpage>872</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.04.030</pub-id><?supplied-pmid 29768175?><pub-id pub-id-type="pmid">29768175</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>MP</given-names></name><name><surname>Khoury</surname><given-names>DS</given-names></name><name><surname>Cromer</surname><given-names>D</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name><name><surname>Kelleher</surname><given-names>AD</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name></person-group><article-title>Functional cure of HIV: the scale of the challenge</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0085-4</pub-id><?supplied-pmid 30410126?><pub-id pub-id-type="pmid">30410126</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Gorgolas</surname><given-names>M</given-names></name><name><surname>Cabello</surname><given-names>A</given-names></name><name><surname>Estrada</surname><given-names>V</given-names></name><name><surname>Ligos</surname><given-names>JM</given-names></name><name><surname>Fernandez-Guerrero</surname><given-names>M</given-names></name><etal/></person-group><article-title>Peripheral T follicular helper cells make a difference in HIV reservoir size between elite controllers and patients on successful cART</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>16799</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17057-y</pub-id><?supplied-pmid 29196729?><pub-id pub-id-type="pmid">29196729</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarancon-Diez</surname><given-names>L</given-names></name><name><surname>Dominguez-Molina</surname><given-names>B</given-names></name><name><surname>Viciana</surname><given-names>P</given-names></name><name><surname>Lopez-Cortes</surname><given-names>L</given-names></name><name><surname>Ruiz-Mateos</surname><given-names>E</given-names></name></person-group><article-title>Long-term persistent elite HIV-controllers: the Right model of functional cure</article-title><source>EBioMedicine</source><year>2018</year><volume>28</volume><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.01.013</pub-id><?supplied-pmid 29361500?><pub-id pub-id-type="pmid">29361500</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>SK</given-names></name><name><surname>Sarr</surname><given-names>AD</given-names></name><name><surname>MacNeil</surname><given-names>A</given-names></name><name><surname>Thakore-Meloni</surname><given-names>S</given-names></name><name><surname>Gueye-Ndiaye</surname><given-names>A</given-names></name><name><surname>Traore</surname><given-names>I</given-names></name><etal/></person-group><article-title>Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections</article-title><source>J Virol</source><year>2007</year><volume>81</volume><issue>10</issue><fpage>5331</fpage><lpage>5338</lpage><pub-id pub-id-type="doi">10.1128/JVI.02789-06</pub-id><?supplied-pmid 17301136?><pub-id pub-id-type="pmid">17301136</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popper</surname><given-names>SJ</given-names></name><name><surname>Sarr</surname><given-names>AD</given-names></name><name><surname>Gueye-Ndiaye</surname><given-names>A</given-names></name><name><surname>Mboup</surname><given-names>S</given-names></name><name><surname>Essex</surname><given-names>ME</given-names></name><name><surname>Kanki</surname><given-names>PJ</given-names></name></person-group><article-title>Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo</article-title><source>J Virol</source><year>2000</year><volume>74</volume><issue>3</issue><fpage>1554</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.3.1554-1557.2000</pub-id><?supplied-pmid 10627569?><pub-id pub-id-type="pmid">10627569</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bender</surname><given-names>AM</given-names></name><name><surname>Simonetti</surname><given-names>FR</given-names></name><name><surname>Kumar</surname><given-names>MR</given-names></name><name><surname>Fray</surname><given-names>EJ</given-names></name><name><surname>Bruner</surname><given-names>KM</given-names></name><name><surname>Timmons</surname><given-names>AE</given-names></name><etal/></person-group><article-title>The Landscape of persistent viral genomes in ART-treated SIV, SHIV, and HIV-2 infections</article-title><source>Cell Host Microbe</source><year>2019</year><volume>26</volume><issue>1</issue><fpage>73</fpage><lpage>85.e4</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.06.005</pub-id><?supplied-pmid 31295427?><pub-id pub-id-type="pmid">31295427</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>TA</given-names></name><name><surname>Sogaard</surname><given-names>OS</given-names></name></person-group><article-title>Clinical interventions in HIV cure research</article-title><source>Adv Exp Med Biol</source><year>2018</year><volume>1075</volume><fpage>285</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/978-981-13-0484-2_12</pub-id><?supplied-pmid 30030798?><pub-id pub-id-type="pmid">30030798</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duvall</surname><given-names>MG</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Alabi</surname><given-names>AS</given-names></name><name><surname>Jeffries</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><issue>11</issue><fpage>6973</fpage><lpage>6981</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.11.6973</pub-id><?supplied-pmid 16709858?><pub-id pub-id-type="pmid">16709858</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duvall</surname><given-names>MG</given-names></name><name><surname>Precopio</surname><given-names>ML</given-names></name><name><surname>Ambrozak</surname><given-names>DA</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Whittle</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Polyfunctional T cell responses are a hallmark of HIV-2 infection</article-title><source>Eur J Immunol</source><year>2008</year><volume>38</volume><issue>2</issue><fpage>350</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1002/eji.200737768</pub-id><?supplied-pmid 18200635?><pub-id pub-id-type="pmid">18200635</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>GM</given-names></name><name><surname>Pinheiro</surname><given-names>S</given-names></name><name><surname>Sayeid-Al-Jamee</surname><given-names>M</given-names></name><name><surname>Alabi</surname><given-names>A</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Sabally</surname><given-names>S</given-names></name><etal/></person-group><article-title>CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype</article-title><source>Eur J Immunol</source><year>2005</year><volume>35</volume><issue>5</issue><fpage>1445</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1002/eji.200526007</pub-id><?supplied-pmid 15832290?><pub-id pub-id-type="pmid">15832290</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Onyango</surname><given-names>C</given-names></name><name><surname>Yindom</surname><given-names>LM</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection</article-title><source>Eur J Immunol</source><year>2010</year><volume>40</volume><issue>7</issue><fpage>1963</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1002/eji.200940295</pub-id><?supplied-pmid 20411566?><pub-id pub-id-type="pmid">20411566</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Yindom</surname><given-names>LM</given-names></name><name><surname>Onyango</surname><given-names>C</given-names></name><name><surname>Sarge-Njie</surname><given-names>R</given-names></name><name><surname>Alabi</surname><given-names>A</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><etal/></person-group><article-title>Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><issue>10</issue><fpage>3067</fpage><lpage>3074</lpage><pub-id pub-id-type="doi">10.1172/JCI32380</pub-id><?supplied-pmid 17823657?><pub-id pub-id-type="pmid">17823657</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Larsen</surname><given-names>O</given-names></name><name><surname>Da Silva</surname><given-names>Z</given-names></name><name><surname>Linder</surname><given-names>H</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>Dias</surname><given-names>F</given-names></name><etal/></person-group><article-title>Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau</article-title><source>Clin Exp Immunol</source><year>2005</year><volume>139</volume><issue>3</issue><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02723.x</pub-id><?supplied-pmid 15730394?><pub-id pub-id-type="pmid">15730394</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>NN</given-names></name><name><surname>Kiviat</surname><given-names>NB</given-names></name><name><surname>Sow</surname><given-names>PS</given-names></name><name><surname>Hawes</surname><given-names>SE</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Diallo-Agne</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>24</issue><fpage>13934</fpage><lpage>13942</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.24.13934-13942.2004</pub-id><?supplied-pmid 15564501?><pub-id pub-id-type="pmid">15564501</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foxall</surname><given-names>RB</given-names></name><name><surname>Cortesao</surname><given-names>CS</given-names></name><name><surname>Albuquerque</surname><given-names>AS</given-names></name><name><surname>Soares</surname><given-names>RS</given-names></name><name><surname>Victorino</surname><given-names>RM</given-names></name><name><surname>Sousa</surname><given-names>AE</given-names></name></person-group><article-title>Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>19</issue><fpage>9795</fpage><lpage>9799</lpage><pub-id pub-id-type="doi">10.1128/JVI.01217-08</pub-id><?supplied-pmid 18653457?><pub-id pub-id-type="pmid">18653457</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Silva</surname><given-names>TI</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Zaidi</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Griffin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection</article-title><source>Blood</source><year>2013</year><volume>121</volume><issue>21</issue><fpage>4330</fpage><lpage>4339</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-472787</pub-id><?supplied-pmid 23558015?><pub-id pub-id-type="pmid">23558015</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angin</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Papagno</surname><given-names>L</given-names></name><name><surname>Versmisse</surname><given-names>P</given-names></name><name><surname>David</surname><given-names>A</given-names></name><name><surname>Bayard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preservation of lymphopoietic potential and virus suppressive capacity by CD8+ T cells in HIV-2-infected controllers</article-title><source>J Immunol</source><year>2016</year><volume>197</volume><issue>7</issue><fpage>2787</fpage><lpage>2795</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600693</pub-id><?supplied-pmid 27566819?><pub-id pub-id-type="pmid">27566819</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>D</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te</surname><given-names>DDS</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><etal/></person-group><article-title>The influence of human leukocyte antigen-types on disease progression among HIV-2 infected patients in Guinea-Bissau</article-title><source>Aids</source><year>2018</year><volume>32</volume><issue>6</issue><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001758</pub-id><?supplied-pmid 29369163?><pub-id pub-id-type="pmid">29369163</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yindom</surname><given-names>LM</given-names></name><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Zaman</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa</article-title><source>J Virol</source><year>2010</year><volume>84</volume><issue>16</issue><fpage>8202</fpage><lpage>8208</lpage><pub-id pub-id-type="doi">10.1128/JVI.00116-10</pub-id><?supplied-pmid 20519398?><pub-id pub-id-type="pmid">20519398</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diouf</surname><given-names>K</given-names></name><name><surname>Sarr</surname><given-names>AD</given-names></name><name><surname>Eisen</surname><given-names>G</given-names></name><name><surname>Popper</surname><given-names>S</given-names></name><name><surname>Mboup</surname><given-names>S</given-names></name><name><surname>Kanki</surname><given-names>P</given-names></name></person-group><article-title>Associations between MHC class I and susceptibility to HIV-2 disease progression</article-title><source>J Hum Virol</source><year>2002</year><volume>5</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><?supplied-pmid 12352262?><pub-id pub-id-type="pmid">12352262</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuvor</surname><given-names>SV</given-names></name><name><surname>van der Sande</surname><given-names>M</given-names></name><name><surname>Rowland-Jones</surname><given-names>S</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name></person-group><article-title>Natural killer cell function is well preserved in asymptomatic human immunodeficiency virus type 2 (HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall</article-title><source>J Virol</source><year>2006</year><volume>80</volume><issue>5</issue><fpage>2529</fpage><lpage>2538</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.5.2529-2538.2006</pub-id><?supplied-pmid 16474159?><pub-id pub-id-type="pmid">16474159</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffar</surname><given-names>S</given-names></name><name><surname>Van der Loeff</surname><given-names>MS</given-names></name><name><surname>Eugen-Olsen</surname><given-names>J</given-names></name><name><surname>Vincent</surname><given-names>T</given-names></name><name><surname>Sarje-Njie</surname><given-names>R</given-names></name><name><surname>Ngom</surname><given-names>P</given-names></name><etal/></person-group><article-title>Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau</article-title><source>AIDS Res Hum Retrovir</source><year>2005</year><volume>21</volume><issue>6</issue><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1089/aid.2005.21.560</pub-id><?supplied-pmid 15989461?><pub-id pub-id-type="pmid">15989461</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leligdowicz</surname><given-names>A</given-names></name><name><surname>Feldmann</surname><given-names>J</given-names></name><name><surname>Jaye</surname><given-names>A</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><etal/></person-group><article-title>Direct relationship between virus load and systemic immune activation in HIV-2 infection</article-title><source>J Infect Dis</source><year>2010</year><volume>201</volume><issue>1</issue><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1086/648733</pub-id><?supplied-pmid 19938978?><pub-id pub-id-type="pmid">19938978</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Frederiksen</surname><given-names>J</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><etal/></person-group><article-title>CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection</article-title><source>Aids</source><year>2016</year><volume>30</volume><issue>16</issue><fpage>2415</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001223</pub-id><?supplied-pmid 27525551?><pub-id pub-id-type="pmid">27525551</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>AE</given-names></name><name><surname>Carneiro</surname><given-names>J</given-names></name><name><surname>Meier-Schellersheim</surname><given-names>M</given-names></name><name><surname>Grossman</surname><given-names>Z</given-names></name><name><surname>Victorino</surname><given-names>RM</given-names></name></person-group><article-title>CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><issue>6</issue><fpage>3400</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.6.3400</pub-id><?supplied-pmid 12218162?><pub-id pub-id-type="pmid">12218162</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachle</surname><given-names>SM</given-names></name><name><surname>Malone</surname><given-names>DF</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>AC</given-names></name><name><surname>Isberg</surname><given-names>PE</given-names></name><name><surname>Biague</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections</article-title><source>Aids</source><year>2016</year><volume>30</volume><issue>11</issue><fpage>1713</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001147</pub-id><?supplied-pmid 27163705?><pub-id pub-id-type="pmid">27163705</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Repits</surname><given-names>J</given-names></name><name><surname>Dabo</surname><given-names>B</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><etal/></person-group><article-title>Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections</article-title><source>J Infect Dis</source><year>2010</year><volume>201</volume><issue>8</issue><fpage>1150</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1086/651430</pub-id><?supplied-pmid 20199244?><pub-id pub-id-type="pmid">20199244</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Repits</surname><given-names>J</given-names></name><name><surname>Dabo</surname><given-names>B</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><etal/></person-group><article-title>Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections</article-title><source>Cytokine</source><year>2009</year><volume>46</volume><issue>3</issue><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2009.03.003</pub-id><?supplied-pmid 19375940?><pub-id pub-id-type="pmid">19375940</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkaya Sahin</surname><given-names>G</given-names></name><name><surname>Holmgren</surname><given-names>B</given-names></name><name><surname>Sheik-Khalil</surname><given-names>E</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>1</issue><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1128/JVI.01640-12</pub-id><?supplied-pmid 23077299?><pub-id pub-id-type="pmid">23077299</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkaya Sahin</surname><given-names>G</given-names></name><name><surname>Holmgren</surname><given-names>B</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name><name><surname>Esbjornsson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>2</issue><fpage>961</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1128/JVI.06315-11</pub-id><?supplied-pmid 22072782?><pub-id pub-id-type="pmid">22072782</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Decker</surname><given-names>JM</given-names></name><name><surname>Zheng</surname><given-names>NN</given-names></name><name><surname>Gottlieb</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>2</issue><fpage>947</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1128/JVI.06155-11</pub-id><?supplied-pmid 22031948?><pub-id pub-id-type="pmid">22031948</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Silva</surname><given-names>TI</given-names></name><name><surname>Aasa-Chapman</surname><given-names>M</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><name><surname>Hue</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><etal/></person-group><article-title>Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>2</issue><fpage>930</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1128/JVI.06126-11</pub-id><?supplied-pmid 22072758?><pub-id pub-id-type="pmid">22072758</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkaya Sahin</surname><given-names>G</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Palm</surname><given-names>AA</given-names></name><name><surname>Vincic</surname><given-names>E</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Medstrand</surname><given-names>P</given-names></name><etal/></person-group><article-title>Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection</article-title><source>AIDS Res Hum Retrovir</source><year>2013</year><volume>29</volume><issue>3</issue><fpage>470</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1089/aid.2012.0219</pub-id><?supplied-pmid 23088167?><pub-id pub-id-type="pmid">23088167</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjorling</surname><given-names>E</given-names></name><name><surname>Scarlatti</surname><given-names>G</given-names></name><name><surname>von Gegerfelt</surname><given-names>A</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Biberfeld</surname><given-names>G</given-names></name><name><surname>Chiodi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection</article-title><source>Virology</source><year>1993</year><volume>193</volume><issue>1</issue><fpage>528</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1006/viro.1993.1160</pub-id><?supplied-pmid 8438591?><pub-id pub-id-type="pmid">8438591</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Brandin</surname><given-names>E</given-names></name><name><surname>Vincic</surname><given-names>E</given-names></name><name><surname>Jansson</surname><given-names>M</given-names></name><name><surname>Blaxhult</surname><given-names>A</given-names></name><name><surname>Gyllensten</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation</article-title><source>J Gen Virol</source><year>2005</year><volume>86</volume><issue>Pt 12</issue><fpage>3385</fpage><lpage>3396</lpage><pub-id pub-id-type="doi">10.1099/vir.0.81259-0</pub-id><?supplied-pmid 16298986?><pub-id pub-id-type="pmid">16298986</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljunggren</surname><given-names>K</given-names></name><name><surname>Biberfeld</surname><given-names>G</given-names></name><name><surname>Jondal</surname><given-names>M</given-names></name><name><surname>Fenyo</surname><given-names>EM</given-names></name></person-group><article-title>Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates</article-title><source>J Virol</source><year>1989</year><volume>63</volume><issue>8</issue><fpage>3376</fpage><lpage>3381</lpage><?supplied-pmid 2746734?><pub-id pub-id-type="pmid">2746734</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>I</given-names></name><name><surname>Tingstedt</surname><given-names>JL</given-names></name><name><surname>Sahin</surname><given-names>GO</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Szojka</surname><given-names>Z</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cross-reactive antibodies with the capacity to mediate HIV-1 envelope glycoprotein-targeted antibody-dependent cellular cytotoxicity identified in HIV-2-infected individuals</article-title><source>J Infect Dis</source><year>2019</year><volume>219</volume><fpage>1749</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz001</pub-id><?supplied-pmid 30715363?><pub-id pub-id-type="pmid">30715363</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Rompay</surname><given-names>KK</given-names></name></person-group><article-title>The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies</article-title><source>AIDS Res Hum Retrovir</source><year>2012</year><volume>28</volume><issue>1</issue><fpage>16</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1089/aid.2011.0234</pub-id><?supplied-pmid 21902451?><pub-id pub-id-type="pmid">21902451</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putkonen</surname><given-names>P</given-names></name><name><surname>Bottiger</surname><given-names>B</given-names></name><name><surname>Warstedt</surname><given-names>K</given-names></name><name><surname>Thorstensson</surname><given-names>R</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><name><surname>Biberfeld</surname><given-names>G</given-names></name></person-group><article-title>Experimental infection of cynomolgus monkeys (<italic>Macaca fascicularis</italic>) with HIV-2</article-title><source>J Acquir Immune Defic Syndr</source><year>1989</year><volume>2</volume><issue>4</issue><fpage>366</fpage><lpage>373</lpage><?supplied-pmid 2526870?><pub-id pub-id-type="pmid">2526870</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franchini</surname><given-names>G</given-names></name><name><surname>Markham</surname><given-names>P</given-names></name><name><surname>Gard</surname><given-names>E</given-names></name><name><surname>Fargnoli</surname><given-names>K</given-names></name><name><surname>Keubaruwa</surname><given-names>S</given-names></name><name><surname>Jagodzinski</surname><given-names>L</given-names></name><etal/></person-group><article-title>Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects</article-title><source>J Virol</source><year>1990</year><volume>64</volume><issue>9</issue><fpage>4462</fpage><lpage>4467</lpage><?supplied-pmid 2117071?><pub-id pub-id-type="pmid">2117071</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locher</surname><given-names>CP</given-names></name><name><surname>Witt</surname><given-names>SA</given-names></name><name><surname>Herndier</surname><given-names>BG</given-names></name><name><surname>Abbey</surname><given-names>NW</given-names></name><name><surname>Tenner-Racz</surname><given-names>K</given-names></name><name><surname>Racz</surname><given-names>P</given-names></name><etal/></person-group><article-title>Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons</article-title><source>J Virol</source><year>2003</year><volume>77</volume><issue>1</issue><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.1.77-83.2003</pub-id><?supplied-pmid 12477812?><pub-id pub-id-type="pmid">12477812</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locher</surname><given-names>CP</given-names></name><name><surname>Witt</surname><given-names>SA</given-names></name><name><surname>Herndier</surname><given-names>BG</given-names></name><name><surname>Tenner-Racz</surname><given-names>K</given-names></name><name><surname>Racz</surname><given-names>P</given-names></name><name><surname>Levy</surname><given-names>JA</given-names></name></person-group><article-title>Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development</article-title><source>Immunol Rev</source><year>2001</year><volume>183</volume><fpage>127</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065x.2001.1830111.x</pub-id><?supplied-pmid 11782253?><pub-id pub-id-type="pmid">11782253</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Neff</surname><given-names>CP</given-names></name><name><surname>Kumar</surname><given-names>DM</given-names></name><name><surname>Habu</surname><given-names>Y</given-names></name><name><surname>Akkina</surname><given-names>SR</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><etal/></person-group><article-title>A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy</article-title><source>Virology</source><year>2017</year><volume>501</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.11.013</pub-id><?supplied-pmid 27912079?><pub-id pub-id-type="pmid">27912079</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaak</surname><given-names>H</given-names></name><name><surname>van der Ende</surname><given-names>ME</given-names></name><name><surname>Boers</surname><given-names>PH</given-names></name><name><surname>Schuitemaker</surname><given-names>H</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>In vitro replication capacity of HIV-2 variants from long-term aviremic individuals</article-title><source>Virology</source><year>2006</year><volume>353</volume><issue>1</issue><fpage>144</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.05.029</pub-id><?supplied-pmid 16814357?><pub-id pub-id-type="pmid">16814357</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamel</surname><given-names>DJ</given-names></name><name><surname>Sankale</surname><given-names>JL</given-names></name><name><surname>Eisen</surname><given-names>G</given-names></name><name><surname>Meloni</surname><given-names>ST</given-names></name><name><surname>Mullins</surname><given-names>C</given-names></name><name><surname>Gueye-Ndiaye</surname><given-names>A</given-names></name><etal/></person-group><article-title>Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity</article-title><source>AIDS Res Hum Retrovir</source><year>2007</year><volume>23</volume><issue>10</issue><fpage>1189</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1089/aid.2007.0037</pub-id><?supplied-pmid 17961103?><pub-id pub-id-type="pmid">17961103</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Harthi</surname><given-names>L</given-names></name><name><surname>Owais</surname><given-names>M</given-names></name><name><surname>Arya</surname><given-names>SK</given-names></name></person-group><article-title>Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells</article-title><source>AIDS Res Hum Retrovir</source><year>1998</year><volume>14</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1089/aid.1998.14.59</pub-id><?supplied-pmid 9453252?><pub-id pub-id-type="pmid">9453252</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>SK</given-names></name><name><surname>Gallo</surname><given-names>RC</given-names></name></person-group><article-title>Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><issue>9</issue><fpage>4486</fpage><lpage>4491</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.9.4486</pub-id><?supplied-pmid 8633095?><pub-id pub-id-type="pmid">8633095</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkotou</surname><given-names>EG</given-names></name><name><surname>Sankale</surname><given-names>JL</given-names></name><name><surname>Mani</surname><given-names>I</given-names></name><name><surname>Gueye-Ndiaye</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>D</given-names></name><name><surname>Essex</surname><given-names>ME</given-names></name><etal/></person-group><article-title>In vitro correlates of HIV-2-mediated HIV-1 protection</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><issue>12</issue><fpage>6797</fpage><lpage>6802</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.12.6797</pub-id><?supplied-pmid 10841574?><pub-id pub-id-type="pmid">10841574</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putkonen</surname><given-names>P</given-names></name><name><surname>Walther</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>SL</given-names></name><name><surname>Nilsson</surname><given-names>C</given-names></name><name><surname>Albert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><issue>9</issue><fpage>914</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1038/nm0995-914</pub-id><?supplied-pmid 7585217?><pub-id pub-id-type="pmid">7585217</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otten</surname><given-names>RA</given-names></name><name><surname>Adams</surname><given-names>DR</given-names></name><name><surname>Kim</surname><given-names>CN</given-names></name><name><surname>Pullium</surname><given-names>JK</given-names></name><name><surname>Sawyer</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Chronic HIV-2 infection protects against total CD4+ cell depletion and rapid disease progression induced by SHIV89.6p challenge</article-title><source>Aids</source><year>2004</year><volume>18</volume><issue>8</issue><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1097/00002030-200405210-00006</pub-id><?supplied-pmid 15166528?><pub-id pub-id-type="pmid">15166528</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Kvist</surname><given-names>A</given-names></name><name><surname>Isberg</surname><given-names>PE</given-names></name><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name><name><surname>Biague</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>3</issue><fpage>224</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113244</pub-id><?supplied-pmid 22808957?><pub-id pub-id-type="pmid">22808957</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Kvist</surname><given-names>A</given-names></name><name><surname>Isberg</surname><given-names>PE</given-names></name><name><surname>Biague</surname><given-names>AJ</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals</article-title><source>Aids</source><year>2014</year><volume>28</volume><issue>7</issue><fpage>949</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000101</pub-id><?supplied-pmid 24812673?><pub-id pub-id-type="pmid">24812673</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>A</given-names></name><name><surname>Furtado</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>D</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><fpage>e001587</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2012-001587</pub-id><?supplied-pmid 23151393?><pub-id pub-id-type="pmid">23151393</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prince</surname><given-names>PD</given-names></name><name><surname>Matser</surname><given-names>A</given-names></name><name><surname>van Tienen</surname><given-names>C</given-names></name><name><surname>Whittle</surname><given-names>HC</given-names></name><name><surname>Schim van der Loeff</surname><given-names>MF</given-names></name></person-group><article-title>Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis</article-title><source>Aids</source><year>2014</year><volume>28</volume><issue>4</issue><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1097/01.SPC.0000432532.87841.78</pub-id><?supplied-pmid 23921613?><pub-id pub-id-type="pmid">23921613</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>PK</given-names></name><name><surname>Kaminski</surname><given-names>R</given-names></name><name><surname>Bella</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Mathews</surname><given-names>S</given-names></name><name><surname>Ahooyi</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>2753</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10366-y</pub-id><?supplied-pmid 31266936?><pub-id pub-id-type="pmid">31266936</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>SG</given-names></name></person-group><article-title>HIV: shock and kill</article-title><source>Nature</source><year>2012</year><volume>487</volume><issue>7408</issue><fpage>439</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/487439a</pub-id><?supplied-pmid 22836995?><pub-id pub-id-type="pmid">22836995</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borducchi</surname><given-names>EN</given-names></name><name><surname>Cabral</surname><given-names>C</given-names></name><name><surname>Stephenson</surname><given-names>KE</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Abbink</surname><given-names>P</given-names></name><name><surname>Ng&#x02019;ang&#x02019;a</surname><given-names>D</given-names></name><etal/></person-group><article-title>Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys</article-title><source>Nature</source><year>2016</year><volume>540</volume><issue>7632</issue><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nature20583</pub-id><?supplied-pmid 27841870?><pub-id pub-id-type="pmid">27841870</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borducchi</surname><given-names>EN</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Nkolola</surname><given-names>JP</given-names></name><name><surname>Cadena</surname><given-names>AM</given-names></name><name><surname>Yu</surname><given-names>WH</given-names></name><name><surname>Fischinger</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys</article-title><source>Nature</source><year>2018</year><volume>563</volume><issue>7731</issue><fpage>360</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0600-6</pub-id><?supplied-pmid 30283138?><pub-id pub-id-type="pmid">30283138</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migueles</surname><given-names>SA</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name></person-group><article-title>Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV</article-title><source>JAMA</source><year>2010</year><volume>304</volume><issue>2</issue><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.925</pub-id><?supplied-pmid 20628133?><pub-id pub-id-type="pmid">20628133</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autran</surname><given-names>B</given-names></name><name><surname>Descours</surname><given-names>B</given-names></name><name><surname>Avettand-Fenoel</surname><given-names>V</given-names></name><name><surname>Rouzioux</surname><given-names>C</given-names></name></person-group><article-title>Elite controllers as a model of functional cure</article-title><source>Curr Opin HIV AIDS</source><year>2011</year><volume>6</volume><issue>3</issue><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1097/COH.0b013e328345a328</pub-id><?supplied-pmid 21460722?><pub-id pub-id-type="pmid">21460722</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>BD</given-names></name></person-group><article-title>Elite control of HIV Infection: implications for vaccines and treatment</article-title><source>Top HIV Med</source><year>2007</year><volume>15</volume><issue>4</issue><fpage>134</fpage><lpage>136</lpage><?supplied-pmid 17720999?><pub-id pub-id-type="pmid">17720999</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>TA</given-names></name><name><surname>Tolstrup</surname><given-names>M</given-names></name><name><surname>Sogaard</surname><given-names>OS</given-names></name></person-group><article-title>Reversal of latency as part of a cure for HIV-1</article-title><source>Trends Microbiol</source><year>2016</year><volume>24</volume><issue>2</issue><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2015.11.003</pub-id><?supplied-pmid 26690612?><pub-id pub-id-type="pmid">26690612</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitman</surname><given-names>MC</given-names></name><name><surname>Lau</surname><given-names>JSY</given-names></name><name><surname>McMahon</surname><given-names>JH</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name></person-group><article-title>Barriers and strategies to achieve a cure for HIV</article-title><source>Lancet HIV</source><year>2018</year><volume>5</volume><issue>6</issue><fpage>e317</fpage><lpage>e328</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(18)30039-0</pub-id><?supplied-pmid 29893245?><pub-id pub-id-type="pmid">29893245</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Hanhauser</surname><given-names>E</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Sirignano</surname><given-names>MN</given-names></name><name><surname>Keating</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases</article-title><source>Ann Intern Med</source><year>2014</year><volume>161</volume><issue>5</issue><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.7326/M14-1027</pub-id><?supplied-pmid 25047577?><pub-id pub-id-type="pmid">25047577</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Gay</surname><given-names>H</given-names></name><name><surname>Ziemniak</surname><given-names>C</given-names></name><name><surname>Sanborn</surname><given-names>KB</given-names></name><name><surname>Somasundaran</surname><given-names>M</given-names></name><name><surname>Rainwater-Lovett</surname><given-names>K</given-names></name><etal/></person-group><article-title>Viremic relapse after HIV-1 remission in a perinatally infected child</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>8</issue><fpage>786</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1413931</pub-id><?supplied-pmid 25693029?><pub-id pub-id-type="pmid">25693029</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>P</given-names></name><name><surname>Gruell</surname><given-names>H</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Pai</surname><given-names>JA</given-names></name><name><surname>Butler</surname><given-names>AL</given-names></name><name><surname>Millard</surname><given-names>K</given-names></name><etal/></person-group><article-title>Combination therapy with anti-HIV-1 antibodies maintains viral suppression</article-title><source>Nature</source><year>2018</year><volume>561</volume><issue>7724</issue><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0531-2</pub-id><?supplied-pmid 30258136?><pub-id pub-id-type="pmid">30258136</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wykes</surname><given-names>MN</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name></person-group><article-title>Immune checkpoint blockade in infectious diseases</article-title><source>Nat Rev Immunol</source><year>2018</year><volume>18</volume><issue>2</issue><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.112</pub-id><?supplied-pmid 28990586?><pub-id pub-id-type="pmid">28990586</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>E</given-names></name><name><surname>Doria-Rose</surname><given-names>N</given-names></name><name><surname>Beninga</surname><given-names>J</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><etal/></person-group><article-title>Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques</article-title><source>Science</source><year>2017</year><volume>358</volume><issue>6359</issue><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1126/science.aan8630</pub-id><?supplied-pmid 28931639?><pub-id pub-id-type="pmid">28931639</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananworanich</surname><given-names>J</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>Eller</surname><given-names>LA</given-names></name><name><surname>Kroon</surname><given-names>E</given-names></name><name><surname>Tovanabutra</surname><given-names>S</given-names></name><name><surname>Bose</surname><given-names>M</given-names></name><etal/></person-group><article-title>HIV DNA set point is rapidly established in acute HIV Infection and dramatically reduced by early ART</article-title><source>EBioMedicine</source><year>2016</year><volume>11</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.07.024</pub-id><?supplied-pmid 27460436?><pub-id pub-id-type="pmid">27460436</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowell</surname><given-names>TA</given-names></name><name><surname>Fletcher</surname><given-names>JL</given-names></name><name><surname>Sereti</surname><given-names>I</given-names></name><name><surname>Pinyakorn</surname><given-names>S</given-names></name><name><surname>Dewar</surname><given-names>R</given-names></name><name><surname>Krebs</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation</article-title><source>J Int AIDS Soc</source><year>2016</year><volume>19</volume><issue>1</issue><fpage>21163</fpage><pub-id pub-id-type="doi">10.7448/IAS.19.1.21163</pub-id><?supplied-pmid 27637172?><pub-id pub-id-type="pmid">27637172</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frange</surname><given-names>P</given-names></name><name><surname>Faye</surname><given-names>A</given-names></name><name><surname>Avettand-Fenoel</surname><given-names>V</given-names></name><name><surname>Bellaton</surname><given-names>E</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Angin</surname><given-names>M</given-names></name><etal/></person-group><article-title>HIV-1 virological remission lasting more than 12&#x000a0;years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report</article-title><source>Lancet HIV</source><year>2016</year><volume>3</volume><issue>1</issue><fpage>e49</fpage><lpage>e54</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(15)00232-5</pub-id><?supplied-pmid 26762993?><pub-id pub-id-type="pmid">26762993</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Petersen</surname><given-names>MS</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te</surname><given-names>DDS</given-names></name><name><surname>Kjerulff</surname><given-names>B</given-names></name><etal/></person-group><article-title>T-cell and B-cell perturbations are similar in ART-naive HIV-1 and HIV-1/2 dually infected patients</article-title><source>Aids</source><year>2019</year><volume>33</volume><issue>7</issue><fpage>1143</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002185</pub-id><?supplied-pmid 30845069?><pub-id pub-id-type="pmid">30845069</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidyavijayan</surname><given-names>KK</given-names></name><name><surname>Cheedarala</surname><given-names>N</given-names></name><name><surname>Babu</surname><given-names>H</given-names></name><name><surname>Precilla</surname><given-names>LK</given-names></name><name><surname>Sathyamurthi</surname><given-names>P</given-names></name><name><surname>Chandrasekaran</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cross type neutralizing antibodies detected in a unique HIV-2 infected individual from India</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>2841</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02841</pub-id><?supplied-pmid 30619250?><pub-id pub-id-type="pmid">30619250</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Kvist</surname><given-names>A</given-names></name><name><surname>Isberg</surname><given-names>PE</given-names></name><name><surname>Nowroozalizadeh</surname><given-names>S</given-names></name><name><surname>Biague</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Effect of HIV-2 infection on HIV-1 disease progression and mortality</article-title><source>Aids</source><year>2014</year><volume>28</volume><issue>4</issue><fpage>614</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000142</pub-id><?supplied-pmid 24469002?><pub-id pub-id-type="pmid">24469002</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Cham</surname><given-names>F</given-names></name><name><surname>McAdam</surname><given-names>S</given-names></name><name><surname>Rostron</surname><given-names>T</given-names></name><name><surname>Rowland-Jones</surname><given-names>S</given-names></name><name><surname>Sabally</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades</article-title><source>J Virol</source><year>1998</year><volume>72</volume><issue>3</issue><fpage>2439</fpage><lpage>2448</lpage><?supplied-pmid 9499105?><pub-id pub-id-type="pmid">9499105</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland-Jones</surname><given-names>S</given-names></name><name><surname>Sutton</surname><given-names>J</given-names></name><name><surname>Ariyoshi</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Gotch</surname><given-names>F</given-names></name><name><surname>McAdam</surname><given-names>S</given-names></name><etal/></person-group><article-title>HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/nm0195-59</pub-id><?supplied-pmid 7584954?><pub-id pub-id-type="pmid">7584954</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borggren</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>SS</given-names></name><name><surname>Heyndrickx</surname><given-names>L</given-names></name><name><surname>Palm</surname><given-names>AA</given-names></name><name><surname>Gerstoft</surname><given-names>J</given-names></name><name><surname>Kronborg</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neutralizing antibody response and antibody-dependent cellular cytotoxicity in HIV-1-infected individuals from Guinea-Bissau and Denmark</article-title><source>AIDS Res Hum Retrovir</source><year>2016</year><volume>32</volume><issue>5</issue><fpage>434</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1089/aid.2015.0118</pub-id><?supplied-pmid 26621287?><pub-id pub-id-type="pmid">26621287</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>VR</given-names></name><name><surname>Jensen</surname><given-names>KJ</given-names></name><name><surname>Jensen</surname><given-names>SS</given-names></name><name><surname>Leo-Hansen</surname><given-names>C</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><etal/></person-group><article-title>Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau</article-title><source>AIDS Res Hum Retrovir</source><year>2013</year><volume>29</volume><issue>11</issue><fpage>1504</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.1089/aid.2013.0076</pub-id><?supplied-pmid 23634822?><pub-id pub-id-type="pmid">23634822</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Krarup</surname><given-names>H</given-names></name><name><surname>Medstrand</surname><given-names>P</given-names></name><name><surname>Sorensen</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><etal/></person-group><article-title>Protease inhibitors or NNRTIs as first-line HIV-1 treatment in West Africa (PIONA): a randomized controlled trial</article-title><source>J Acquir Immune Defic Syndr</source><year>2018</year><volume>79</volume><issue>3</issue><fpage>386</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001820</pub-id><?supplied-pmid 30044302?><pub-id pub-id-type="pmid">30044302</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>MN</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><name><surname>Laursen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Soluble macrophage mannose receptor (sCD206/sMR) as a biomarker in human immunodeficiency virus infection</article-title><source>J Infect Dis</source><year>2018</year><volume>218</volume><issue>8</issue><fpage>1291</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy318</pub-id><?supplied-pmid 29800140?><pub-id pub-id-type="pmid">29800140</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Andersen</surname><given-names>MN</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><name><surname>Jakobsen</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Brief report: macrophage activation in HIV-2-infected patients is less affected by antiretroviral treatment-sCD163 in HIV-1, HIV-2, and HIV-1/2 dually infected patients</article-title><source>J Acquir Immune Defic Syndr</source><year>2016</year><volume>72</volume><issue>3</issue><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000000939</pub-id><?supplied-pmid 26825178?><pub-id pub-id-type="pmid">26825178</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Furtado</surname><given-names>A</given-names></name><name><surname>Camara</surname><given-names>C</given-names></name><name><surname>Luneborg-Nielsen</surname><given-names>M</given-names></name><name><surname>Sodemann</surname><given-names>M</given-names></name><name><surname>Gerstoft</surname><given-names>J</given-names></name><etal/></person-group><article-title>Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis</article-title><source>Int J Infect Dis</source><year>2013</year><volume>17</volume><issue>10</issue><fpage>e907</fpage><lpage>e912</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2013.05.003</pub-id><?supplied-pmid 23816410?><pub-id pub-id-type="pmid">23816410</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Oliveira</surname><given-names>I</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva Te</surname><given-names>D</given-names></name><name><surname>Correia</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations</article-title><source>Bull World Health Organ</source><year>2014</year><volume>92</volume><issue>12</issue><fpage>909</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.2471/BLT.14.135749</pub-id><?supplied-pmid 25552775?><pub-id pub-id-type="pmid">25552775</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Oliveira</surname><given-names>I</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Cohort profile: the Bissau HIV cohort&#x02014;a cohort of HIV-1, HIV-2 and co-infected patients</article-title><source>Int J Epidemiol</source><year>2015</year><volume>44</volume><issue>3</issue><fpage>756</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1093/ije/dyu201</pub-id><?supplied-pmid 25342251?><pub-id pub-id-type="pmid">25342251</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mild</surname><given-names>M</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>Medstrand</surname><given-names>P</given-names></name></person-group><article-title>HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrations</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>2</issue><fpage>e17025</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0017025</pub-id><?supplied-pmid 21365013?><pub-id pub-id-type="pmid">21365013</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><name><surname>Laursen</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Lack of awareness of treatment failure among HIV-1-infected patients in Guinea-Bissau&#x02014;a retrospective cohort study</article-title><source>J Int AIDS Soc</source><year>2015</year><volume>18</volume><fpage>20243</fpage><pub-id pub-id-type="doi">10.7448/IAS.18.1.20243</pub-id><?supplied-pmid 26426197?><pub-id pub-id-type="pmid">26426197</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Aunsborg</surname><given-names>J</given-names></name><name><surname>Mendes</surname><given-names>DV</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><etal/></person-group><article-title>High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau&#x02014;a cohort study from West Africa</article-title><source>Pan Afr Med J</source><year>2016</year><volume>25</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.11604/pamj.2016.25.40.8329</pub-id><?supplied-pmid 28154729?><pub-id pub-id-type="pmid">28154729</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Differential effects of sex in a West African cohort of HIV-1, HIV-2 and HIV-1/2 dually infected patients: men are worse off</article-title><source>Trop Med Int Health</source><year>2016</year><volume>21</volume><issue>2</issue><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1111/tmi.12646</pub-id><?supplied-pmid 26616349?><pub-id pub-id-type="pmid">26616349</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>D</given-names></name><name><surname>Hviid</surname><given-names>CJ</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te</surname><given-names>DDS</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Increased mortality among HIV infected patients with cryptococcal antigenemia in Guinea-Bissau</article-title><source>Pan Afr Med J</source><year>2018</year><volume>29</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.11604/pamj.2018.29.18.14099</pub-id><?supplied-pmid 29662603?><pub-id pub-id-type="pmid">29662603</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denton</surname><given-names>PW</given-names></name><name><surname>Sogaard</surname><given-names>OS</given-names></name><name><surname>Tolstrup</surname><given-names>M</given-names></name></person-group><article-title>Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research</article-title><source>J Transl Med</source><year>2016</year><volume>14</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s12967-016-0807-y</pub-id><?supplied-pmid 26861779?><pub-id pub-id-type="pmid">26861779</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Martinez-Arias</surname><given-names>W</given-names></name><name><surname>Vincic</surname><given-names>E</given-names></name><name><surname>Biague</surname><given-names>AJ</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Frequent CXCR138 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease-indication of an evolving epidemic in West Africa</article-title><source>Retrovirology</source><year>2010</year><volume>7</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-7-23</pub-id><?supplied-pmid 20307309?><pub-id pub-id-type="pmid">20307309</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>KL</given-names></name><name><surname>de Silva</surname><given-names>TI</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Whittle</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><etal/></person-group><article-title>Low-bias RNA sequencing of the HIV-2 genome from blood plasma</article-title><source>J Virol</source><year>2018</year><volume>93</volume><issue>1</issue><fpage>e00677-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00677-18</pub-id><?supplied-pmid 30333167?><pub-id pub-id-type="pmid">30333167</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palm</surname><given-names>AA</given-names></name><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cocirculation of several similar but unique HIV-1 recombinant forms in Guinea-Bissau revealed by near full-length genomic sequencing</article-title><source>AIDS Res Hum Retrovir</source><year>2015</year><volume>31</volume><issue>9</issue><fpage>938</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1089/aid.2015.0073</pub-id><?supplied-pmid 26066756?><pub-id pub-id-type="pmid">26066756</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palm</surname><given-names>AA</given-names></name><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Kvist</surname><given-names>A</given-names></name><name><surname>Isberg</surname><given-names>PE</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><etal/></person-group><article-title>Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3/CRF02_AG compared with sub-subtype A3</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>5</issue><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit416</pub-id><?supplied-pmid 23935204?><pub-id pub-id-type="pmid">23935204</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindman</surname><given-names>JL</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><name><surname>Da Silva</surname><given-names>ZJ</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name></person-group><article-title>Declining prevalence rates of syphilis among police officers in Guinea-Bissau, West Africa, 1990&#x02013;2010</article-title><source>Sex Transm Dis</source><year>2013</year><volume>40</volume><issue>10</issue><fpage>794</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1097/OLQ.0000000000000012</pub-id><?supplied-pmid 24275730?><pub-id pub-id-type="pmid">24275730</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>B</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Camara</surname><given-names>C</given-names></name><name><surname>Monteiro</surname><given-names>M</given-names></name><name><surname>Biai</surname><given-names>A</given-names></name><name><surname>Alves</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><issue>2</issue><fpage>e000636</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2011-000636</pub-id><?supplied-pmid 22436137?><pub-id pub-id-type="pmid">22436137</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linderholm</surname><given-names>L</given-names></name><name><surname>Biague</surname><given-names>A</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>Bergman</surname><given-names>A</given-names></name><name><surname>Jakobsson</surname><given-names>K</given-names></name></person-group><article-title>Human exposure to persistent organic pollutants in West Africa&#x02014;a temporal trend study from Guinea-Bissau</article-title><source>Environ Int</source><year>2010</year><volume>36</volume><issue>7</issue><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/j.envint.2010.04.020</pub-id><?supplied-pmid 20537392?><pub-id pub-id-type="pmid">20537392</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>Bamba</surname><given-names>S</given-names></name><name><surname>Da Silva</surname><given-names>ZJ</given-names></name><name><surname>Koivula</surname><given-names>T</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name></person-group><article-title>Higher mortality in HIV-2/HTLV-1 co-infected patients with pulmonary tuberculosis in Guinea-Bissau, West Africa, compared to HIV-2-positive HTLV-1-negative patients</article-title><source>Int J Infect Dis</source><year>2010</year><volume>14</volume><issue>Suppl 3</issue><fpage>e142</fpage><lpage>e147</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2009.11.040</pub-id><?supplied-pmid 20395161?><pub-id pub-id-type="pmid">20395161</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gronborg</surname><given-names>HL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Egedal</surname><given-names>JH</given-names></name><name><surname>Correia</surname><given-names>FG</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Krarup</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prevalence and clinical characteristics of CMV coinfection among HIV infected individuals in Guinea-Bissau: a cross-sectional study</article-title><source>Trop Med Int Health</source><year>2018</year><volume>23</volume><issue>8</issue><fpage>896</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1111/tmi.13082</pub-id><?supplied-pmid 29851192?><pub-id pub-id-type="pmid">29851192</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Hepatitis C prevalence among HIV-infected patients in Guinea-Bissau: a descriptive cross-sectional study</article-title><source>Int J Infect Dis</source><year>2014</year><volume>28</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2014.06.007</pub-id><?supplied-pmid 25223805?><pub-id pub-id-type="pmid">25223805</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te Dda</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Lewin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>e99971</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0099971</pub-id><?supplied-pmid 24915064?><pub-id pub-id-type="pmid">24915064</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MM</given-names></name><name><surname>Olesen</surname><given-names>JS</given-names></name><name><surname>Kjerulff</surname><given-names>B</given-names></name><name><surname>Byberg</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><etal/></person-group><article-title>HTLV prevalence is no longer following the decreasing HIV prevalence&#x02014;20&#x000a0;years of retroviral surveillance in Guinea-Bissau, West Africa</article-title><source>Acta Trop</source><year>2019</year><volume>192</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2019.02.015</pub-id><?supplied-pmid 30771284?><pub-id pub-id-type="pmid">30771284</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>A</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Katzenstein</surname><given-names>TL</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te Dda</surname><given-names>S</given-names></name><name><surname>Correira</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Clinical presentation and opportunistic infections in HIV-1, HIV-2 and HIV-1/2 dual seropositive patients in Guinea-Bissau</article-title><source>Infect Dis</source><year>2016</year><volume>48</volume><issue>8</issue><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1080/23744235.2016.1180708</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiniche</surname><given-names>D</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Krarup</surname><given-names>H</given-names></name><name><surname>Handberg</surname><given-names>A</given-names></name><name><surname>Ostergaard</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diabetes mellitus and impaired fasting glucose in ART-naive patients with HIV-1, HIV-2 and HIV-1/2 dual infection in Guinea-Bissau: a cross-sectional study</article-title><source>Trans R Soc Trop Med Hyg</source><year>2016</year><volume>110</volume><issue>4</issue><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1093/trstmh/trw017</pub-id><?supplied-pmid 27076509?><pub-id pub-id-type="pmid">27076509</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelmson</surname><given-names>S</given-names></name><name><surname>Mansson</surname><given-names>F</given-names></name><name><surname>Lopatko Lindman</surname><given-names>J</given-names></name><name><surname>Biai</surname><given-names>A</given-names></name><name><surname>Esbjornsson</surname><given-names>J</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prevalence of HIV-1 pretreatment drug resistance among treatment naive pregnant women in Bissau, Guinea Bissau</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>10</issue><fpage>e0206406</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0206406</pub-id><?supplied-pmid 30379960?><pub-id pub-id-type="pmid">30379960</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Tolstrup</surname><given-names>M</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te Dda</surname><given-names>S</given-names></name><name><surname>Ellermann-Eriksen</surname><given-names>S</given-names></name><etal/></person-group><article-title>High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau</article-title><source>Virol J</source><year>2015</year><volume>12</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0273-9</pub-id><?supplied-pmid 25889017?><pub-id pub-id-type="pmid">25889017</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindman</surname><given-names>J</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Kjerulff</surname><given-names>B</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><etal/></person-group><article-title>Performance of Bio-Rad HIV-1/2 Confirmatory Assay in HIV-1, HIV-2 and HIV-1/2 dually reactive patients&#x02014;comparison with INNO-LIA and immunocomb discriminatory assays</article-title><source>J Virol Methods</source><year>2019</year><volume>268</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2019.03.005</pub-id><?supplied-pmid 30871983?><pub-id pub-id-type="pmid">30871983</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Bjarnason Obinah</surname><given-names>MP</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te Dda</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Performance of 3 rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa</article-title><source>J Acquir Immune Defic Syndr</source><year>2014</year><volume>65</volume><issue>1</issue><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3182a97b81</pub-id><?supplied-pmid 23982658?><pub-id pub-id-type="pmid">23982658</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te David</surname><given-names>DS</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discriminatory rapid tests cause HIV-type misclassification-evaluation of three rapid tests using clinical samples from Guinea-Bissau</article-title><source>Trans R Soc Trop Med Hyg</source><year>2019</year><pub-id pub-id-type="doi">10.1093/trstmh/trz041</pub-id><?supplied-pmid 31162598?><pub-id pub-id-type="pmid">31162598</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Te</surname><given-names>DS</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><name><surname>Christiansen</surname><given-names>M</given-names></name><etal/></person-group><article-title>The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections</article-title><source>HIV Med</source><year>2018</year><volume>19</volume><issue>6</issue><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1111/hiv.12606</pub-id><?supplied-pmid 29573304?><pub-id pub-id-type="pmid">29573304</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Mendes</surname><given-names>DV</given-names></name><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name></person-group><article-title>Comment on Gautheret-Dejean et al.: Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections</article-title><source>J Med Virol.</source><year>2016</year><volume>88</volume><issue>3</issue><fpage>367</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1002/jmv.24365</pub-id><?supplied-pmid 26366875?><pub-id pub-id-type="pmid">26366875</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Norrgren</surname><given-names>H</given-names></name><name><surname>Dias</surname><given-names>F</given-names></name><name><surname>Biberfeld</surname><given-names>G</given-names></name></person-group><article-title>Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area</article-title><source>Aids</source><year>1997</year><volume>11</volume><issue>15</issue><fpage>1815</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1097/00002030-199715000-00005</pub-id><?supplied-pmid 9412699?><pub-id pub-id-type="pmid">9412699</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther-Jallow</surname><given-names>L</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>Z</given-names></name><name><surname>Biberfeld</surname><given-names>G</given-names></name></person-group><article-title>High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa</article-title><source>AIDS Res Hum Retrovir</source><year>1999</year><volume>15</volume><issue>11</issue><fpage>957</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1089/088922299310467</pub-id><?supplied-pmid 10445807?><pub-id pub-id-type="pmid">10445807</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyrehave</surname><given-names>C</given-names></name><name><surname>Rasmussen</surname><given-names>DN</given-names></name><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Correia</surname><given-names>FG</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nonadherence is associated with lack of HIV-Related knowledge: a cross-sectional study among HIV-infected individuals in Guinea-Bissau</article-title><source>J Int Assoc Provid AIDS Care</source><year>2016</year><volume>15</volume><issue>4</issue><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1177/2325957415599211</pub-id><?supplied-pmid 26297492?><pub-id pub-id-type="pmid">26297492</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honge</surname><given-names>BL</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Nordentoft</surname><given-names>PB</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>D</given-names></name><name><surname>da Silva</surname><given-names>ZJ</given-names></name><etal/></person-group><article-title>Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><issue>10</issue><fpage>e003499</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-003499</pub-id><?supplied-pmid 24163204?><pub-id pub-id-type="pmid">24163204</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordentoft</surname><given-names>PB</given-names></name><name><surname>Engell-Sorensen</surname><given-names>T</given-names></name><name><surname>Jespersen</surname><given-names>S</given-names></name><name><surname>Correia</surname><given-names>FG</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><etal/></person-group><article-title>Assessing factors for loss to follow-up of HIV infected patients in Guinea-Bissau</article-title><source>Infection</source><year>2017</year><volume>45</volume><issue>2</issue><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/s15010-016-0949-0</pub-id><?supplied-pmid 27743308?><pub-id pub-id-type="pmid">27743308</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>DN</given-names></name><name><surname>da Silva</surname><given-names>Te D</given-names></name><name><surname>Rodkjaer</surname><given-names>L</given-names></name><name><surname>Oliveira</surname><given-names>I</given-names></name><name><surname>Medina</surname><given-names>C</given-names></name><name><surname>Barfod</surname><given-names>T</given-names></name><etal/></person-group><article-title>Barriers and facilitators to antiretroviral therapy adherence among patients with HIV in Bissau, Guinea-Bissau: a qualitative study</article-title><source>Afr J AIDS Res</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2989/16085906.2013.815405</pub-id><?supplied-pmid 25871305?><pub-id pub-id-type="pmid">25871305</pub-id></element-citation></ref></ref-list></back></article>